Document And Entity Information - USD ($) $ in Millions	12 Months Ended
Document And Entity Information - USD ($) $ in Millions	Dec. 31, 2017	Jun. 06, 2018	Jun. 30, 2017
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Entity Registrant Name	ACURA PHARMACEUTICALS, INC
Entity Central Index Key	0000786947
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 4.2
Trading Symbol	ACUR
Entity Common Stock, Shares Outstanding		21,033,528

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Assets
Cash and cash equivalents	$ 2,220	$ 2,681
Restricted cash equivalents (Note 7)	0	2,500
Trade accounts receivable (net of allowances of $- and $7)	0	23
Collaboration revenue receivable	0	79
Royalty receivable	71	50
Inventories (net of allowances of $- and $32) (Note 4)	0	309
Prepaid expenses and other current assets	275	268
Total current assets	2,566	5,910
Income tax receivable	135	0
Property, plant and equipment, net (Note 5)	679	867
Intangible asset (net of accumulated amortization of $776 and $569) (Note 3)	1,224	1,431
Total assets	4,604	8,208
Liabilities:
Accounts payable	3	77
Accrued expenses (Note 6)	939	703
Accrued interest - current	700	0
Other current liabilities	41	27
Sales returns liability	254	304
Debt - current portion (net of discounts) (Note 7)	2,694	2,376
Total current liabilities	4,631	3,487
Debt - non-current portion (net of discounts) (Note 7)	0	2,979
Accrued interest - non-current portion	0	559
Total liabilities	4,631	7,025
Current liabilities:
Commitments and contingencies (Note 14)
Stockholders’ (deficit) equity:
Common stock - $.01 par value per share; 100,000 shares authorized, 20,796 and 11,834 shares issued and outstanding at 2017 and 2016, respectively	208	118
Additional paid-in capital	380,145	375,763
Accumulated deficit	(380,380)	(374,698)
Total stockholders’ (deficit) equity	(27)	1,183
Total liabilities and stockholders’ (deficit) equity	$ 4,604	$ 8,208

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounts receivable, net of allowances	$ 0	$ 7
Inventory Valuation Reserves	0	32
Finite-lived intangible assets accumulated amortization	$ 776	$ 569
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000	100,000
Common stock, shares issued	20,796	11,834
Common stock, shares outstanding	20,796	11,834

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenues:
License fee revenue	$ 2,500	$ 3,500
Collaboration revenue	59	392
Royalty revenue	300	149
Product sales, net	107	423
Total revenues, net	2,966	4,464
Cost and expenses:
Cost of sales (excluding inventory provisions)	128	451
Inventory provisions (Note 4)	0	26
Research and development	3,721	4,028
Selling, marketing, general and administrative	4,342	6,516
Total costs and expenses	8,191	11,021
Operating loss	(5,225)	(6,557)
Non-operating income (expense):
Interest and investment income	4	60
Interest expense (Note 7)	(596)	(893)
Other income	0	2
Total other expense, net	(592)	(831)
Loss before income taxes	(5,817)	(7,388)
Provision (benefit) for income taxes	(135)	0
Net loss	(5,682)	(7,388)
Other comprehensive income:
Unrealized gains on marketable securities	0	65
Comprehensive loss	$ (5,682)	$ (7,323)
Net loss per share:
Basic	$ (0.36)	$ (0.62)
Diluted	$ (0.36)	$ (0.62)
Denominator:
Basic	15,903	11,870
Diluted	15,903	11,870

CONSOLIDATED STATEMENTS OF CHANGES IN ACCUMULATED STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional paid-in capital	Accumulated deficit	Accumulated Other Comprehensive Income (Loss)
Balance at Dec. 31, 2015	$ 7,900	$ 118	$ 375,157	$ (367,310)	$ (65)
Balance (in shares) at Dec. 31, 2015		11,801
Net loss	(7,388)	$ 0	0	(7,388)	0
Other comprehensive income	65	0	0	0	65
Noncash share-based compensation	588	0	588	0	0
Net distribution of common stock pursuant to restricted stock unit award plan	18	$ 0	18	0	0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)		33
Balance at Dec. 31, 2016	1,183	$ 118	375,763	(374,698)	0
Balance (in shares) at Dec. 31, 2016		11,834
Net loss	(5,682)	$ 0	0	(5,682)	0
Noncash share-based compensation	464	0	464	0	0
Issuance of shares and warrants under private placement	4,000	$ 89	3,911	0	0
Issuance of shares and warrants under private placement (in shares)		8,913
Net distribution of common stock pursuant to restricted stock unit award plan	8	$ 1	7	0	0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)		49
Balance at Dec. 31, 2017	$ (27)	$ 208	$ 380,145	$ (380,380)	$ 0
Balance (in shares) at Dec. 31, 2017		20,796

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash Flows from Operating Activities:
Net loss	$ (5,682)	$ (7,388)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	87	138
Provision to reduce inventory to net realizable value	0	26
Provision for sales returns	49	99
Provision for fixed asset impairment	0	82
Noncash share-based compensation	464	588
Amortization of debt discount and deferred debt issue costs	99	145
Amortization of bond premium in marketable securities	0	31
Amortization of intangible asset	207	207
(Gain) loss on disposals of property, plant and equipment	(2)	1
(Gain) on sales of marketable securities	0	(2)
Changes in assets and liabilities:
Trade accounts receivable, net	23	19
Collaboration revenue receivable	79	(43)
Royalty receivable	(21)	(45)
Accrued investment income	0	37
Inventories	103	(59)
Prepaid expenses and other current assets	(7)	149
Income tax receivable	(135)	0
Other assets	0	175
Accounts payable	(74)	(33)
Accrued expenses	236	139
Accrued interest - current and long term	141	172
Other current liabilities	22	(1)
Sales returns liability	(99)	0
Net cash used in operating activities	(4,510)	(5,563)
Cash Flows from Investing Activities:
Proceeds from sales and maturities of marketable securities	0	10,873
Proceeds from transfer of equipment to licensee	103	0
Proceeds from transfer of inventory to licensee	206	0
Capital expenditures	0	(75)
Net cash provided by investing activities	309	10,798
Cash Flows from Financing Activities:
Proceeds from distribution of restricted stock units	0	1
Principal payments on loan maturing December 1, 2018	(2,760)	(2,540)
Issuance of common stock	4,000	0
Net cash provided by (used in) financing activities	1,240	(2,539)
Net (decrease) increase in cash and cash equivalents	(2,961)	2,696
Cash and cash equivalents at beginning of year	2,681	2,485
Cash and cash equivalents at end of year	2,220	2,681
Cash paid during the year for:
Interest on loan maturing December 1, 2018	355	576
Income taxes, net of refunds	$ 0	$ 0

OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2017

Description Of Operation And Summary Of Significant Accounting Policies Disclosure [Abstract]

OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 – OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principal Operations

Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “Acura”, “We”, or “Our”) is a specialty pharmaceutical company engaged in the research and development of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Limitx™ Technology is intended to address methods of product tampering associated with opioid abuse by retarding the release of active drug ingredients when too many tablets are accidently or purposefully ingested. Our Aversion® Technology is intended to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Our Impede® Technology is directed at minimizing the extraction and conversion of pseudoephedrine into methamphetamine.

⋅

Our Limitx Technology is in development with the immediate-release hydrocodone bitartrate and acetaminophen as a lead Limitx product candidate due to its larger market size than our prior lead product and its known prevalence of oral excessive tablet abuse.

⋅

Our Aversion Technology has been licensed to Egalet Corporation for use in Oxaydo® Tablets (oxycodone HCl, CII), and is the first approved immediate-release oxycodone product in the United States with abuse deterrent labeling. Oxaydo is currently approved by the FDA for marketing in the United States in 5mg and 7.5mg strengths. Egalet launched Oxaydo in the United States late in the third quarter of 2015. (see Note 3).

⋅

Our Impede Technology is used in Nexafed® Tablets (30mg pseudoephedrine HCl) and Nexafed® Sinus Pressure + Pain Tablets (30/325mg pseudoephedrine HCl and acetaminophen). We have licensed to MainPointe Pharmaceuticals, LLC, or MainPointe, our Impede Technology in the United States and Canada to commercialize our Nexafed products (with options to acquire other Impede Technology Products and other territories), pursuant to a License, Commercialization and Option Agreement, or the MainPointe Agreement, entered into on March 16, 2017. (see Note 3).

Basis of Presentation and Substantial Doubt in Going Concern

The accompanying consolidated financial statements of the Company have been prepared assuming the Company will continue as a going concern and in accordance with generally accepted accounting principles in the United States of America. The going concern basis of presentation assumes that we will continue in operation one year after the date these financial statements are issued and we will be able to realize our assets and discharge our liabilities and commitments in the normal course of business. As of December 31, 2017, we had cash and cash equivalents of $2.2 million, working capital deficit of $2.1 million and an accumulated deficit of $380.4 million. We had a loss from operations of $5.2 million and a net loss of $5.7 million for the year ended December 31, 2017. We have suffered recurring losses from operations and have not generated positive cash flows from operations. We anticipate operating losses to continue for the foreseeable future.

We have a term loan with Oxford Finance LLC (“Oxford” or the “Lender”) and as of December 31, 2017 and May 14, 2018, the outstanding principal balance is $2.7 million and $1.8 million, respectively. A $795 thousand balloon interest payment is due to Oxford on December 1, 2018. Our term loan agreement with Oxford contains customary affirmative and negative covenants. One such covenant is that the Company must submit on an annual basis to Oxford, within 120 days after the end of its fiscal year, audited consolidated financial statements, together with an unqualified audit opinion from an independent registered public accounting firm, or the Unqualified Audit Opinion Covenant. Per the term loan agreement an audit opinion with an explanatory paragraph noting substantial doubt about the Company’s ability to continue in business (the “going concern opinion”) is deemed to violate the Unqualified Audit Opinion Covenant. Failure to comply with the Unqualified Audit Opinion Covenant is a breach of the term loan agreement and unless such covenant or breach is waived, Oxford would have the option of accelerating the debt under the term loan agreement and initiating enforcement collection actions, foreclosing on collateral (which includes most assets of the Company) and, among other things, preventing the Company from using any funds in its bank or securities accounts. On March 16, 2017, we and Oxford entered into a third amendment to the Loan Agreement, or the Third Amendment. Pursuant to the Third Amendment (i) we granted Oxford a lien on our intellectual property, (ii) Oxford provided a waiver of compliance with the Unqualified Audit Opinion Covenant in connection with our receipt of our auditor’s going concern opinion for our 2016 financial statements and (iii) Oxford consented to the terms of the MainPointe Agreement.

During the second quarter of 2018, we borrowed a a total of $1.0 million from John Schutte, a principal of MainPointe and our largest shareholder, and in conjunction with such loan, we entered into of a fourth amendment to our term loan agreement with Oxford, pursuant to which Oxford granted a similar waiver of compliance with the Unqualified Audit Opinion Covenant for our 2017 financial statements and extended the period in which we could deliver financial statements for 2017 to 160 days after year’s end (instead of 120 days). (see Notes 7 and 15). With the net proceeds of approximately $1.0 million to the Company resulting from the loan from Mr. Schutte, we expect our cash will only be sufficient to fund operations into late June 2018.

These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. We must seek sources to raise additional financing and seek to enter into license or collaboration agreements with third parties relating to our technologies. The Company is exploring a variety of capital raising and other transactions to provide additional funding to continue operations. These include potential private offerings of common stock to accredited and/or institutional investors and licensing transactions with pharmaceutical company partners for our proprietary technologies, including Limitx. We are actively seeking a licensing partner for our Limitx technology, with the objective of receiving an upfront license fee, development milestone payments and royalties on the net sales of products utilizing the Limitx technology, similar to the Egalet Agreement. We are also exploring licensing or selling select assets and intellectual property in an effort to raise capital and reduce operating expenses. Finally, the Company continues to evaluate the potential for a strategic transaction which may involve the Company being acquired in a merger or asset purchase transaction. No assurance can be given that we will be successful in completing any one or more of such transactions on acceptable terms, if at all, or if completed, that such transactions will provide payments to the Company sufficient to fund continued operations. In the absence of the Company’s completion of one or more of such transactions, there will be substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued, and the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. An extended delay or cessation of the Company’s continuing product development efforts will have a material adverse effect on the Company’s financial condition and results of operations.

In view of the matters described above, management has concluded that substantial doubt exists with respect to the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The recoverability of a major portion of the recorded asset amounts shown in the Company’s accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its funding requirements on a continuous basis, to maintain existing financing and to succeed in its future operations. The Company’s financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The consolidated financial statements include the accounts of our wholly-owned subsidiary, Acura Pharmaceutical Technologies Inc., after elimination of intercompany accounts and transactions. Amounts presented have been rounded to the nearest thousand, where indicated, except share and per share data.

Reclassifications

Certain reclassifications have been made to the prior year’s amounts to conform to the current year's presentation.

Use of Estimates

Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Management periodically evaluates estimates used in the preparation of the consolidated financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based on such periodic evaluations.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains deposits in federally insured financial institutions which are in excess of federally insured limits. However, management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.

Cash and Cash Equivalents

The Company considers cash and cash equivalents to include cash in financial institutions and money market funds, and considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Our cash and cash equivalents are governed by our investment policy as approved by our Board of Directors. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.

Fair Value Measurements

The Company’s financial instruments consist primarily of cash and cash equivalents, receivables from trade, royalties and collaboration, trade accounts payable, and our long-term debt. The carrying amounts of these financial instruments are representative of their respective fair values due to their relatively short maturities.

Share-based Compensation Expense

We have several share-based compensation plans covering stock options and RSUs for our employees and directors, which are described more fully in Note 11.

We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the market price of our common stock on the date of grant, less its exercise cost.

Our share-based compensation expense recognized in the Company’s results of operations from all types of noncash and cash-portioned instruments issued comprised the following (in thousands):

	Year Ended December 31,
	2017		2016
Research and development expense:
Stock option awards	$	136	$	167
RSU awards		3		-
	$	139	$	167

Selling, marketing, general and administrative expense:
Stock option awards		203		301
RSU awards		156		143
	$	359	$	444

Total share-based compensation expense	$	498	$	611

Property, Plant and Equipment

Property, plant and equipment are stated at cost, less accumulated depreciation. We have no leasehold improvements. Betterments are capitalized and maintenance and repairs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation is removed from the respective accounts.

Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the related assets. The estimated useful lives of the major classification of depreciable assets are:

Building and improvements	10 - 40 years
Land and improvements	20 - 40 years
Machinery and equipment	7 - 10 years
Scientific equipment	5 - 10 years
Computer hardware and software	3 - 10 years

Intangible and Long-Lived Assets

Long-lived assets such as the intangible asset and property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability of the assets to be held and used is measured by a comparison of the carrying amount of the asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying value of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. We recorded an impairment charge of $82 thousand in the fourth quarter of 2016 on equipment having a net book value of a like amount. We had no impairment charges during the year 2017.

License Fee Revenue

On signing the MainPointe Agreement in March 2017, MainPointe paid us an upfront licensing fee of $2.5 million. The payment was non-refundable and non-creditable when made and we had no further requirements to earn the payment. The amount was recognized as revenue when received. (see Note 3).

In October 2016, the Company entered into a worldwide License Agreement (the “KemPharm Agreement”) pursuant to which we licensed our Aversion® technology to KemPharm for its use in the development and commercialization of three products using two of KemPharm’s prodrug candidates. KemPharm has also been granted an option to extend the KemPharm Agreement to cover two additional prodrug candidates. KemPharm paid us $3.5 million upon signing the KemPharm Agreement. The payment was non-refundable and non-creditable when made and we had no further requirements to earn the payment. The amount was recognized as revenue when received. (see Note 3).

Collaboration Revenue

Collaboration revenue is derived from reimbursement of development expenses, such as under our agreement with Bayer, and are recognized when costs are incurred pursuant to the agreements. The ongoing research and development services being provided under the collaboration are priced at fair value based upon the reimbursement of expenses incurred pursuant to the collaboration agreements. We recognized $59 thousand and $392 thousand of collaboration revenue during the year 2017 and 2016, respectively.

Royalty Revenue

We recognize revenue from royalties based on our licensees' sales of our products or products using our technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. If royalties cannot be reasonably estimated or collectability of a royalty amount is not reasonably assured, royalties are recognized as revenue when the cash is received.

In connection with our Collaboration and License Agreement with Egalet to commercialize Oxaydo tablets we will receive a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year over the term of the agreement (excluding net sales resulting from any co-promotion efforts by us). We recognize royalty revenue each calendar quarter based on net sales reported to us by Egalet in accordance with the agreement. Egalet’s first commercial sale of Oxaydo occurred in October 2015 and we have recorded royalties of $281 thousand and $149 thousand on net sales for the years 2017 and 2016, respectively. (see Note 3).

In connection with the MainPointe Agreement, which occurred on March 16, 2017, we are receiving a royalty of 7.5% on net sales of the licensed products over the term of the agreement. Such royalty shall be payable for sales made during each calendar quarter and payment will be remitted within forty-five (45) days after the end of the quarter to which it relates. We have recorded royalties of $19 thousand for the year 2017. (see Note 3).

Net Product Sales

Nexafed was launched in mid-December 2012 and Nexafed Sinus Pressure + Pain was launched in February 2015. Prior to entering into the MainPointe Agreement, we sold our Nexafed products in the United States to wholesale pharmaceutical distributors as well as directly to chain drug stores. Our Nexafed products were sold subject to the right of return usually for a period of up to twelve months after the product expiration. Both products had an initial shelf life of twenty-four months from the date of manufacture, which shelf life had been extended to thirty-six months for Nexafed product supplied to us during 2016 from one of the Company’s contract manufacturers. Prior to entering into the MainPointe Agreement, we recognized revenue from our Nexafed product line sales when the price was fixed and determinable at the date of sale, title and risk of ownership were transferred to the customer, and returns could be reasonably estimated, which generally occurred at the time of product shipment.

Advertising and Shipping/Handling Costs

The Company records the cost of its advertising efforts in marketing expenses when services are performed or goods are delivered. We record shipping and handling costs in selling expenses. As of mid-March 2017 we no longer manufacture, distribute or sell the Nexafed product line as the Company granted MainPointe an exclusive license to our Impede technology to commercialize our Nexafed products in the U.S. and Canada. The amounts recorded as selling expenses from the shipments of the Nexafed product line during each of the years 2017 and 2016 were not material.

Deferred Debt Issuance Costs and Debt Discount

Deferred debt issuance costs include costs of debt financing undertaken by the Company, including legal fees, placement fees and other direct costs of the financing. Debt discount is the value attributable to warrants issued in conjunction with the financing. Debt issuance costs and debt discount are amortized into interest expense over the term of the related debt using the effective interest method. Deferred debt issuance costs and debt discount are presented on the balance sheets as a direct reduction against the debt.

Research and Development Activities

Research and Development (“R&;D”) costs include internal R&;D activities, external Contract Research Organization (“CRO”) services and their clinical research and investigative sites, and other activities. Internal R&;D activity costs can include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, formulation work, depreciation, salaries, benefits, insurance and share-based compensation expenses. CRO activity costs can include preclinical laboratory experiments and clinical trial studies. Other activity costs can include regulatory consulting, regulatory legal counsel, cost of acquiring, developing and manufacturing pre-clinical trial materials, costs of manufacturing scale-up, and cost sharing expenses under license agreements. Internal R&;D costs and other activity costs are charged to expense as incurred. We make payments to the CRO's based on agreed upon terms and may include payments in advance of a study starting date. Payments in advance will be reflected in the consolidated financial statements as prepaid expenses. We review and charge to expense accrued CRO costs and clinical trial study costs based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Our accrued CRO costs are subject to revisions as such studies progress towards completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.

We did not have prepaid CRO costs nor did we have prepaid clinical trial study expenses at either December 31, 2017 or 2016. We did not have any obligations under non-cancelable arrangements at December 31, 2017.

Income Taxes

We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and the income tax basis of assets and liabilities and are measured using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse. Additionally, net operating loss and tax credit carryforwards are reported as deferred income tax assets. The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At December 31, 2017 and 2016, 100% of all remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of net operating loss carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized.

Basic and Diluted Net Loss Per Share

Basic net loss per share is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to vested Restricted Stock Units (“RSUs”). (see Note 12). Diluted net loss per share is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2017 or 2016 as the Company reported a net loss for each year and including the effects of common stock equivalents in the diluted net loss per share calculation would have been antidilutive.

Customer Concentration

In March 2017, we licensed our Nexafed product line to MainPointe Pharmaceuticals LLC. Until that time our accounts receivable arose from our sales of our Nexafed product line and represent amounts due from wholesalers in the health care and pharmaceuticals industries and from chain drug stores. The Company has performed a credit evaluation of its customers and we have not experienced any losses on uncollectable accounts in 2017 or 2016.

Sales to certain of our customers during 2016 accounting for 10% or more of our annual product sales, whether the product shipment was recognized immediately as a sales or as a deferred sale, is presented below.

Customer	2016
Rite Aid Corporation		55	%
Cardinal Health, Inc.		13	%
McKesson Corporation		10	%

Trade accounts receivable from certain of our customers at December 31, 2016 accounting for 10% or more of our gross accounts receivable is presented below.

Customer	2016
AmerisourceBergen Corporation		35	%
McKesson Corporation		24	%
Cardinal Health, Inc.		19	%
The Kroger Co.		18	%
Rite Aid Corporation		**

Recent Accounting Pronouncements

New accounting standards which have been adopted on or before December 31, 2017

Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern

In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-15 which explicitly requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist which raise substantial doubt about an entity’s ability to continue as a going concern and to provide related disclosures. The amendments in this update are effective for the first annual period ending after December 15, 2017, and for annual periods and interim periods thereafter. Early application is permitted. The Company early adopted the guidance for its financial statement disclosures in the fourth quarter of 2016.

Statements of Cash Flows - Restricted Cash

In November 2016, the FASB issued ASU 2016-18 which requires that at statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new standard will be effective for annual and interim periods, within those fiscal years beginning after December 15, 2017 but early adoption is permitted. The Company early adopted the guidance in the first quarter of 2017 which did not have a material impact on the Company’s consolidated financial statements or related footnote disclosures.

Business Combinations – Clarifying the Definition of a Business

In January 2017, the FASB issued ASU No. 2017-01 which clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The amendments in this update provide a screen to determine when an integrated set of assets and activities (collectively referred to as a “set”), is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. ASU 2017-01 is effective for annual periods beginning after December 15, 2017, but early application of the amendments in this update is allowed. The amendments in this update should be applied prospectively on or after the effective date. The Company early adopted this new standard on January 1, 2017 which did not have a material impact on the Company’s consolidated financial statements.

Simplication of Employee Share-Based Payment Accounting

In March 2016, the FASB issued ASU 2016-09 which provides for simplification of certain aspects of employee share-based payment accounting including income taxes, classification of awards as either equity or liabilities, accounting for forfeitures and classification on the statement of cash flows. ASU 2016-09 is to be applied either prospectively, retrospectively or using a modified retrospective transition approach depending on the area covered in this update. The new standard was effective for annual and interim periods, within those fiscal years, beginning after December 15, 2016. The Company adopted the guidance in the first quarter of 2017 which did not have a material impact on the Company’s consolidated financial statements.

Simplifying the Measurement of Inventory

In July 2015, the FASB issued ASU No. 2015-11, which simplifies the measurement of inventory, applying to inventories for which cost is determined by methods other than last-in first-out (LIFO) and the retail inventory method (RIM), specifying that an entity should measure inventory at the lower of cost and net realizable value instead of at the lower of cost or market. The amendments in this ASU were effective for annual and interim periods, within those fiscal years, beginning after December 15, 2016. The Company adopted the guidance of the standard in the first quarter of 2017 which did not have a material impact on the Company’s consolidated financial statements.

New accounting standards which have not yet been adopted on or before December 31, 2017

Revenue from Contracts with Customers

In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which deferred the effective date of ASU 2014-09 for all entities by one year. This update is effective for public business entities for annual reporting periods beginning after December 15, 2017, including interim periods within those reporting periods. The ASU permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). The ASU also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required for customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. We have completed the process of evaluating the effect of the adoption and determined there were no changes required to our reported revenues as a result of the adoption. The majority of our revenue arrangements generally consist of performance obligations related to license our drug technologies. Based on our evaluation process and review of our contracts with customers, the timing and amount of revenue recognized under the new standard is materially consistent with our revenue recognition policy under previous guidance. We adopted the new standard effective January 1, 2018, using the modified retrospective approach, and will expand our consolidated financial statement disclosures in order to comply with ASU 2014-09. We have determined the adoption of the new guidance will not have a material impact on our results of operations, cash flows, or financial position.

Scope of Modification Accounting, Stock Based Compensation

In May 2017, the FASB issued ASU No. 2017-09 which provides guidance as to how an entity should apply modified accounting in Topic 718 when changing the terms and conditions of its share-based payment awards. The guidance clarifies that modification accounting will be applied if the value, vesting conditions or classification of the award changes. The ASU is effective for annual reporting periods, including interim periods within those annual periods, beginning after December 15, 2017 but early adoption is permitted. The Company has not adopted the standard and does not anticipate that the standard will have a material effect, if any, on our consolidated financial statements and related disclosures.

Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments

In August 2016, the FASB issued ASU 2016-15 which clarifies existing guidance on how companies present and classify certain cash receipts and cash payments in the statement of cash flows by addressing specific cash flow issues in an effort to reduce diversity in practice, including guidance on debt prepayment or extinguishment costs and contingent consideration payments made after a business combination. This update is effective for annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company expects that the standard will not have an impact on the Company’s consolidated financial statements and related footnote disclosures.

Leases

In February 2016, the FASB issued ASU 2016-02 which establishes a comprehensive new lease accounting model. The new standard will require most leases (with the exception of leases with terms of one year or less) to be recognized on the balance sheet as a lease liability with a corresponding right-of-use asset. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018 but early adoption is permitted. The new standard must be presented using the modified retrospective transition method existing at or entered into after the beginning of the earliest comparative period presented in the financial statements, but it does not require transition accounting for leases that expire prior to the date of initial application. Upon adoption, operating leases will be reported on the balance sheet as a gross-up of assets and liabilities. The Company is currently evaluating the impact that the standard will have on the consolidated financial statements and related footnote disclosures.

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS

12 Months Ended

Dec. 31, 2017

Research and Development Disclosure [Abstract]

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT

NOTE 3 – LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS

MainPointe Agreement covering Nexafed Product Line

In March 2017, we and MainPointe entered into the MainPointe Agreement, pursuant to which we granted MainPointe an exclusive license to our Impede technology to commercialize our Nexafed products in the U.S. and Canada. We also conveyed to MainPointe our existing inventory and equipment relating to our Nexafed products. MainPointe is responsible for all development, manufacturing and commercialization activities with respect to products covered by the Agreement.

On signing the MainPointe Agreement, MainPointe paid us an upfront licensing fee of $2.5 million plus approximately $309 thousand for inventories and equipment being transferred to them. The MainPointe Agreement also provides for our receipt of a 7.5% royalty on net sales of the licensed products. The royalty payment for each product will expire on a country-by-country basis when the Impede® patent rights for such country have expired or are no longer valid; provided that if no Impede patent right exists in a country, then the royalty term for that country will be the same as the royalty term for the United States. After the expiration of a royalty term for a country, MainPointe retains a royalty free license to our Impede® technology for products covered by the Agreement in such country.

MainPointe has the option to expand the licensed territory beyond the United States and Canada to the European Union (and the United Kingdom), Japan and South Korea for payments of $1.0 million, $500 thousand and $250 thousand, respectively. In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). Such Option Products include the product candidate Loratadine with pseudoephedrine. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.

The MainPointe Agreement may be terminated by either party for a material breach of the other party, or by Acura if MainPointe challenges certain of its patents. Upon early termination of the MainPointe Agreement, MainPointe’s licenses to the Impede technology and all products will terminate. Upon termination, at Acura’s request the parties will use commercially reasonable efforts to transition the Nexafed® and Nexafed® Sinus Pressure + Pain products back to Acura.

KemPharm Agreement Covering Certain Opioid Prodrugs

In October 2016, we and KemPharm Inc. (”KemPharm”) entered into a worldwide License Agreement (the “KemPharm Agreement”) pursuant to which we licensed our Aversion® technology to KemPharm for its use in the development and commercialization of three products using 2 of KemPharm’s prodrug candidates. KemPharm has also been granted an option to extend the KemPharm Agreement to cover two additional prodrug candidates. KemPharm is responsible for all development, manufacturing and commercialization activities.

Upon execution of the KemPharm Agreement, KemPharm paid us an upfront payment of $3.5 million. If KemPharm exercises its option to use our Aversion technology with more than the two licensed prodrugs, then KemPharm will pay us up to $1.0 million for each additional prodrug license. In addition, we will receive from KemPharm a low single digit royalty on commercial sales by KemPharm of products developed using our Aversion technology under the KemPharm Agreement. KemPharm’s royalty payment obligations commence on the first commercial sale of a product using our Aversion technology and expire, on a country-by-country basis, upon the expiration of the last to expire patent claim of the Aversion technology covering a product in such country, at which time the license for the particular product and country becomes fully paid and royalty free.

The KemPharm Agreement expires upon the expiration of KemPharm’s royalty payment obligations in all countries. Either party may terminate the KemPharm Agreement in its entirety if the other party materially breaches the KemPharm Agreement, subject to applicable cure periods. Acura or KemPharm may terminate the KemPharm Agreement with respect to the U.S. and other countries if the other party challenges the patents covering the licensed products. KemPharm may terminate the KemPharm Agreement for convenience on ninety (90) days prior written notice. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the KemPharm Agreement provides for termination of our license grant to KemPharm.

Egalet Agreement covering Oxaydo

In April 2014, we terminated an agreement with Pfizer and the return to us of Aversion Oxycodone (formerly known as Oxecta®) and all Aversion product rights in exchange for a one-time termination payment of $2.0 million. Our termination payment of $2.0 million has been recorded in our consolidated financial statements as an intangible asset and is being amortized over the remaining useful life of the patent covering Aversion Oxycodone, which was 9.7 years as of the date the agreement was terminated. We have recorded annual amortization expense of $208 thousand for each of the years 2017 and 2016. Annual amortization of the patent for the years 2018 through 2021 is expected to approximate $208 thousand each year.

In January 2015, we and Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation, or collectively Egalet, entered into a Collaboration and License Agreement (the “Egalet Agreement”) to commercialize Aversion Oxycodone (formerly known as Oxecta®) under our tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Egalet Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Egalet and Egalet is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States. Eaglet launched Oxaydo in the United States late in the third quarter of 2015.

In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet is responsible for the fees and expenses relating to the Oxaydo NDA and product line extensions of Oxaydo, provided that Egalet will pay a substantial majority of the fees and expenses and we will pay for the remaining fees and expense relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States. Egalet will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion.

Egalet paid us a $5.0 million license fee upon signing of the Egalet Agreement and on October 9, 2015, paid us a $2.5 million milestone in connection with the first commercial sale of Oxaydo. We will be entitled to a one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. We are receiving from Egalet a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year (excluding net sales resulting from our co-promotion efforts). In any calendar year of the agreement in which net sales exceed a specified threshold, we will receive a double digit royalty on all Oxaydo net sales in that year (excluding net sales resulting from our co-promotion efforts). If we exercise our co-promotion rights, we will receive a share of the gross margin attributable to incremental Oxaydo net sales from our co-promotion activities. Egalet’s royalty payment obligations commence on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of the last to expire valid patent claim covering Oxaydo in such country (or if there are no patent claims in such country, then upon the expiration of the last valid claim in the United States or the date when no valid and enforceable listable patent in the FDA’s Orange Book remains with respect to Oxaydo). Royalties will be reduced upon the entry of generic equivalents, as well as for payments required to be made by Egalet to acquire intellectual property rights to commercialize Oxaydo, with an aggregate minimum floor.

The Egalet Agreement expires upon the expiration of Egalet’s royalty payment obligations in all countries. Either party may terminate the Egalet Agreement in its entirety if the other party breaches a payment obligation, or otherwise materially breaches the Egalet Agreement, subject to applicable cure periods, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. We also may terminate the Egalet Agreement with respect to the U.S. and other countries if Egalet materially breaches its commercialization obligations. Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalet’s supply of Oxaydo for a transition period.

Terminated Bayer Agreement Covering Methamphetamine Resistant Pseudoephedrine-containing Product

In June 2015, we and Bayer entered into a License and Development Agreement (the “Bayer Agreement”) granting Bayer an exclusive worldwide license to our Impede Technology for use in an undisclosed methamphetamine resistant pseudoephedrine–containing product (the “Bayer Licensed Product”) and providing for the joint development of such product utilizing our Impede Technology for the U.S. market. In June 2017, we received Bayer’s notice of termination of the Bayer Agreement pursuant to its convenience termination right exercised prior to the Company’s completion of its product development obligations under the Bayer Agreement. We have received reimbursement of certain of our development costs under the Bayer Agreement.

Following Bayer’s termination of the Bayer Agreement the Bayer License Product is now subject to MainPointe’s option rights under the MainPointe Agreement.

INVENTORIES

12 Months Ended

Dec. 31, 2017

Inventory Disclosure [Abstract]

INVENTORIES

NOTE 4 – INVENTORIES

We did not have inventories at December 31, 2017 as all our inventories were transferred to MainPointe under the MainPointe Agreement in March 2017. (See Note 3). Inventories at December 31, 2016 are stated at the lower of cost (first-in, first-out method) or net realizable value. We write down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results.

Our purchases of ingredients and other materials required in our development and clinical trial activities are expensed as incurred.

Inventories at December 31, 2016 are summarized as follows (in thousands):

	December 31,
	2016
Raw and packaging materials	$	98
Finished goods		243
Total		341
Less: reserve for finished goods		(32)
Net inventories	$	309

Inventory reserve activity during the years ended December 31, 2017 and 2016 was as follows (in thousands):

	2017		2016
Beginning of year	$	32	$	70
Reserve expense - finished goods		-		26
		32		96
Inventory write-offs - finished goods		(32)		(64)
End of year	$	-	$	32

PROPERTY, PLANT AND EQUIPMENT

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

NOTE 5 – PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment is summarized as follows (in thousands):

	December 31,
	2017		2016
Building and improvements	$	1,273	$	1,273
Scientific equipment		598		598
Computer hardware and software		107		109
Machinery and equipment		275		568
Land and improvements		162		162
Other personal property		70		70
Office equipment		27		27
		2,512		2,807
Less: impairment reserve		-		(82)
Less: accumulated depreciation		(1,833)		(1,858)
Total property, plant and equipment, net	$	679	$	867

The impairment reserve of $82 thousand at December 31, 2016 was for specific machinery and other equipment which was used in the production of our Nexafed product line and which was not conveyed to MainPointe under the MainPointe Agreement. During 2017, we applied the reserve against the disposal of these specific assets. We do not have leasehold improvements nor do we have capitalized leases. Costs of betterments are capitalized while maintenance costs and repair costs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation will be removed from the respective accounts.

Depreciation expense was approximately $0.1 million for each of the years ended December 31, 2017 and 2016.

DEBT

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

DEBT

NOTE 7 – DEBT

Loan due December 1, 2018

In December 2013, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $10.0 million (the “Term Loan”). The Term Loan accrues interest at a fixed rate of 8.35% per annum (with a default rate of 13.35% per annum). The Company was required to make monthly interest-only payments until April 1, 2015 (“Amortization Date”) and on the Amortization Date, the Company began to make payments of principal and accrued interest in equal monthly installments of $260 thousand sufficient to amortize the Term Loan through the maturity date of December 1, 2018. All unpaid principal and accrued and unpaid interest with respect to the Term Loan is due and payable in full on December 1, 2018. As security for its obligations under the initial Loan Agreement (prior to the Third Amendment), the Company granted Lender a security interest in substantially all of its existing and after-acquired assets, exclusive of its intellectual property assets, which the Company was prohibited from pledging to others. Upon the execution of the Loan Agreement, we issued to the Lender warrants to purchase an aggregate of up to 60 thousand shares of our common stock at an exercise price equal to $7.98 per share (after adjustment for our one-for-five reverse stock split effectuated in 2015) (the “Warrants”). We recorded $400 thousand as debt discount associated with the relative fair value of the Warrants and are amortizing it to interest expense over the term of the loan using the loan’s effective interest rate. The Warrants are immediately exercisable for cash or by net exercise and will expire December 27, 2020.

In January 2015, we and Oxford entered into an amendment to the Loan Agreement. Pursuant to the amendment, (i) the exercise price of the warrants was lowered from $7.98 to $2.52 per share (the average closing price of our common stock on Nasdaq for the 10 trading days preceding the date of the amendment and after giving effect to our one-for-five reverse stock split) and we recorded additional debt discount of $33 thousand representing the fair value of the warrant modification, (ii) we agreed to maintain $2.5 million cash reserves until such time as we have repaid $5.0 million in principal of the Term Loan, and (iii) the Lender consented to the terms of our Collaboration and License Agreement with Egalet relating to our Oxaydo product.

In October 2016, we and Oxford entered into a second amendment to the Loan Agreement (the “Second Amendment”). Pursuant to the Second Amendment, (i) the requirement that we maintain a $2.5 million cash balance reserve until such time as $5.0 million in principal was repaid under the Term Loan was modified so that the $2.5 million cash balance reserve remains in place until we raise an additional $6.0 million (excluding payments received under the KemPharm Agreement) through the issuance of equity securities and from upfront payments under license, joint venture, collaboration or other partnering transactions, provided that at least $3.0 million of such amount must be raised through the issuance and sale of our equity securities, and (ii) the Lender consented to the terms of our Agreement with KemPharm. In July 2017, the Company completed a private placement of its equity units to an investor, each unit consisting of one share of common stock and a warrant to purchase one-fifth of a share of common stock. The net proceeds to the Company from the private offering was approximately $4.0 million. Giving effect to the $2.5 million upfront payment received from MainPointe pursuant to the MainPointe Agreement and the approximate $4.0 million in net proceeds from the July 2017 private offering, the Company has satisfied the condition in the Second Amendment to the Oxford Loan Agreement to waive the $2.5 million cash reserve requirement.

In March 2017, we and Oxford entered into a third amendment to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment (i) we granted Oxford a lien on our intellectual property, (ii) Oxford provided a waiver of compliance with the Unqualified Audit Opinion Covenant in connection with our receipt of our auditor’s going concern opinion for our 2016 financial statements and (iii) Oxford consented to the terms of the MainPointe Agreement. Under the Loan Agreement, an audit opinion with an explanatory paragraph noting substantial doubt about the Company’s ability to continue in business is deemed to violate the Unqualified Audit Opinion Covenant.

In the second quarter of 2018, in connection with a $1.0 million loan extended by John Schutte, we and Oxford entered into a fourth amendment to the Loan Agreement. Pursuant to the fourth amendment, Oxford provided a waiver of compliance with the unqualified audit opinion covenant in connection with our receipt of our auditor’s opinion with a going concern explanatory paragraph for our 2017 financial statements and allowed us to deliver financial statements up to 160 days after year end, instead of 120 days after year end. See Note 15 for a discussion of this transaction.

The Company may voluntarily prepay the Term Loan in full, but not in part, and any prepayment is subject to a prepayment premium equal to 1% of the principal prepaid. In addition, at the maturity, termination or upon voluntary or mandatory prepayment of the Term Loan the Company must pay the Lender an additional one-time interest payment of $795 thousand. We are accruing additional monthly interest expense over the term of the loan for this additional one-time interest payment using the loan’s effective cash interest rate. As of December 31, 2017 and 2016, we have accumulated and accrued $700 thousand and $559 thousand, respectively, of this additional interest.

The Company was obligated to pay customary lender fees and expenses, including a one-time facility fee of $50 thousand and the Lender’s expenses in connection with the Loan Agreement. Combined with the Company’s own expenses and a $100 thousand consulting placement fee, the Company incurred $231 thousand in deferred debt issue costs. We are amortizing these costs, including debt modification additional costs, into interest expense over the term of the loan using the loan’s effective interest rate of 10.16%.

The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, limits or restrictions on the Company’s ability to incur liens, incur indebtedness, pay dividends, redeem stock, and merge or consolidate and dispose of assets. In addition, it contains customary events of default that entitles the Lender to cause any or all of the Company’s indebtedness under the Loan Agreement to become immediately due and payable. The events of default (some of which are subject to applicable grace or cure periods), include, among other things, non-payment defaults, covenant defaults (including breach of the Unqualified Audit Opinion Covenant), a material adverse change in the Company, bankruptcy and insolvency defaults and material judgment defaults.

Our debt activity at December 31, 2017 is summarized below (in thousands):

Current Debt	Current		Long-term		Total
Balance at Jan. 1, 2017	$	2,521	$	2,979	$	5,500
Principal payments		(2,760)		-		(2,760)
Classification		2,979		(2,979)		-
Balance at Dec. 31, 2017	$	2,740	$	-	$	2,740

Debt Discount	Current		Long-term		Total
Balance at Jan. 1, 2017	$	(98)	$	-	$	(98)
Amortization expense		66		-		66
Classification		-		-		-
Balance at Dec. 31, 2017	$	(32)	$	-	$	(32)

Deferred Debt Issuance Costs	Current		Long-term		Total
Balance at Jan. 1, 2017	$	(47)	$	-	$	(47)
Amortization expense		33		-		33
Classification		-		-		-
Balance at Dec. 31, 2017	$	(14)	$	-	$	(14)

Current Debt, net at Dec. 31, 2017	$	2,694	$	-	$	2,694

Our interest expense consisted of the following (in thousands):

	Year Ended December 31,
	2017		2016
Interest expense:
Term loan	$	497	$	748
Debt discount		66		95
Debt issue costs		33		50
Total interest expense	$	596	$	893

RELATED PARTY TRANSACTIONS

12 Months Ended

Dec. 31, 2017

RELATED PARTY TRANSACTIONS

NOTE 8 – RELATED PARTY TRANSACTIONS

In July 2017, we completed a $4.0 million private placement with John Schutte (sometimes referred to as the “Investor”), consisting of 8,912,655 units (“Units) of the Company, at a price of $0.4488 per Unit (the “Transaction). Each Unit consists of one share of Common Stock and a Warrant to purchase one fifth (0.2) of a share of Common Stock. The issue price of the Units was equal to 85% of the average last sale price of our Common Stock for the five trading days prior to completion of the Transaction. The Warrants are immediately exercisable at a price of $0.528 per share (which equals the average last sale price of the Company’s Common Stock for the five trading days prior to completion of the Transaction) and expire five years after issuance (subject to earlier expiration in event of certain acquisitions). We have assigned a relative fair value of $495 thousand to the warrants out of the total $4.0 million proceeds from the private placement transaction and have accounted these warrants as equity. The Transaction was completed through a private placement to an accredited investor and was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended and/or Regulation D promulgated under the Securities Act of 1933.

Investor is a principal of MainPointe, a Kentucky limited liability company. In March 2017, we granted MainPointe an exclusive license to our Impede technology to commercialize our Nexafed® and Nexafed® Sinus Pressure + Pain Products in the United States and Canada for an upfront licensing fee of $2.5 million plus approximately $309 thousand for transferred inventory and equipment. The Company will receive a 7.5% royalty on sales of licensed products. MainPointe also has options to expand the territory and products covered for additional sums. Included in the reported revenue for the year 2017 is $13 thousand of royalty revenue from MainPointe. (See Note 3).

As part of the closing of the Transaction, the Company, Essex Woodlands Health Ventures V, L.P. (“Essex”) and Galen Partners III, L.P. (“Galen”) amended and restated the existing Voting Agreement including such parties to provide for the Investor to join as a party (as so amended, the “Second Amended and Restated Voting Agreement”). The Second Amended and Restated Voting Agreement provides that our Board of Directors shall remain comprised of no more than seven members (subject to certain exceptions), (i) one of whom is the Company’s Chief Executive Officer, (ii) three of whom are independent under Nasdaq standards, and (iii) one of whom shall be designated by each of Essex, Galen and Investor, and the parties to such agreement would vote for such persons. The right of each of Essex, Galen and Investor to designate one director to our Board will continue as long as he or it and their affiliates collectively hold at least 600,000 shares of our Common Stock (including warrants exercisable for such shares). Immanuel Thangaraj is the designee of Essex. Galen has not designated a director and lost that right in December 2017 when it disposed of its shares. Investor has not designated a director as of the date of filing of this Report. Once such shareholder no longer holds such securities, the additional forfeited seat would become a seat for an independent director to thereafter be nominated to the Board of Directors from time to time by the then current directors and as applicable, to be elected by the directors to fill the vacancy created by the forfeited seat or submitted to the vote of shareholders at the Company’s next annual meeting.

During the second quarter of 2018, we borrowed a total of $1.0 million from John Schutte and issued a promissory note in that principal amount to him. See Note 15 for a discussion of this transaction.

EMPLOYEE BENEFIT PLAN

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

EMPLOYEE BENEFIT PLAN

NOTE 9 – EMPLOYEE BENEFIT PLAN

We have a 401(k) and Profit-Sharing Plan (the “Plan”) for our employees. Employees may elect to make a basic contribution of up to 80% of their annual earnings subject to certain regulatory restrictions on their total contribution. The Plan provides that the Company can make discretionary matching contributions along with a discretionary profit-sharing contribution. We did not contribute a matching contribution or a profit sharing contribution to the Plan during the years 2017 or 2016.

COMMON STOCK WARRANTS

12 Months Ended

Dec. 31, 2017

Stockholders Equity Note [Abstract]

COMMON STOCK WARRANTS

NOTE 10 – COMMON STOCK WARRANTS

Our warrant activity during the years ended December 31, 2017 and 2016 is shown below (in thousands except price data):

	December 31,
	2017				2016
	Number		WAvg Exercise Price		Number		WAvg Exercise Price
Outstanding, Jan. 1		60	$	2.52		60	$	2.52
Issued		1,782		0.53		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Modification		-		-		-		-
Outstanding, Dec. 31		1,842	$	0.59		60	$	2.52

In connection with the issuance of the $10.0 million secured promissory notes in December 2013, we issued common stock purchase warrants (“warrants”) exercisable for 60 thousand shares of our common stock having an exercise price of $2.52 per share (after giving effect to our one-for-five reverse stock split) with an expiration date in December 2020. See Note 8 for a discussion of the reduction of the exercise price of these warrants to $2.52 per share. These warrants contain a cashless exercise feature.

As part of our July 2017 private placement transaction with John Schutte, we issued warrants to purchase 1,782,531 shares of our common stock. The Warrants are immediately exercisable at a price of $0.528 per share and expire five years after issuance (see Note 8). We have assigned a relative fair value of $495 thousand to the warrants out of the total $4.0 million proceeds from the private placement transaction and have accounted these warrants as equity.

SHARE-BASED COMPENSATION EXPENSE

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

SHARE-BASED COMPENSATION

NOTE 11 – SHARE-BASED COMPENSATION EXPENSE

Stock Option Plans

We maintain various stock option plans. A summary of our stock option plans as of December 31, 2017 and 2016 and for the year then ended consisted of the following (in thousands except exercise price):

	Year Ended December 31,
	2017				2016
	Number of Options		Weighted Average Exercise Price		Number of Options		Weighted Average Exercise Price
Outstanding, Jan. 1		1,397	$	15.67		1,198	$	15.67
Granted		185		0.45		199		0.92
Exercised		(1)		0.92		-		-
Forfeited or expired		(87)		7.02		-		-
Outstanding, Dec. 31		1,494	$	12.33		1,397	$	15.67
Exercisable, Dec. 31		1,224	$	14.92		1,062	$	17.41

The following table summarizes information about unvested stock options outstanding at December 31, 2017 (in thousands except price data):

	Number of Options Not Exercisable		Weighted Average Fair Value

Outstanding at Jan. 1, 2017		335	$	1.18
Granted		185		0.45
Vested		(236)		1.34
Forfeited		(14)		1.05
Outstanding at Dec. 31, 2017		270	$	0.46

We estimate the option’s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, forfeitures, volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities utilized in the Black-Scholes model are based on the historical volatility of our common stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected life of the grants is derived from historical exercise activity. Historically, the majority of our stock options have been held until their expiration date.

The assumptions used in the Black-Scholes model to determine fair value for the 2017 and 2016 stock option grants were:

	2017			2016
Expected dividend yield		0.0	%		0.0	%
Risk-free interest rates		1.8	%		2.3	%
Average expected volatility		88	%		85	%
Expected term (years)		5			10
Weighted average grant date fair value	$	0.31		$	0.77

The option awards which are vested and outstanding had an instrinsic value of $0 at December 31, 2017. The total remaining unrecognized compensation cost on unvested option awards outstanding at December 31, 2017 was approximately $100 thousand, and is expected to be recognized in the Company’s operating expense in varying amounts over the next eleven months remaining in the requisite service periods. There were 1 thousand option awards exercised during 2017 and there was no option award exercise activity during 2016.

Restricted Stock Unit Award Plans

We have two Restricted Stock Unit Award Plans for our employees and non-employee directors, a 2017 Restricted Stock Unit Award Plan (the “2017 RSU Plan”) and a 2014 Restricted Stock Unit Award Plan (the “2014 RSU Plan”). Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. Our non-employee director awards allow for non-employee directors to receive payment in cash, instead of stock, for up to 40% of each RSU award. The portion of the RSU awards subject to cash settlement are recorded as a liability in the Company’s balance sheet as they vest and being marked-to-market each reporting period until they are distributed. The liability was $41 thousand and $27 thousand at December 31, 2017 and 2016, respectively.

The compensation cost to be incurred on a granted RSU without a cash settlement option is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized to expense and recorded to additional paid-in capital over the vesting period of the RSU award.

A summary of the grants under the RSU Plans as of December 31, 2017 and 2016, and for the year then ended consisted of the following (in thousands):

	Year Ended December 31,
	2017				2016
	Number of RSUs		Number of Vested RSUs		Number of RSUs		Number of Vested RSUs
Outstanding, Jan. 1		91		91		45		45
Granted		438		-		88		-
Distributed		(67)		(67)		(42)		(42)
Vested		-		238		-		88
Forfeited or expired		-		-		-		-
Outstanding, Dec. 31		462		262		91		91

2017 Restricted Stock Unit Award Plan

Our 2017 RSU Plan was approved by shareholders in November 2017 and permits the grant of up to 1.5 million shares of our common stock pursuant to awards under the 2017 RSU Plan. As of December 31, 2017, approximately 1.3 million shares are available for award under the 2017 RSU Plan.

Information about the awards under the 2017 RSU Plan is as follows:

⋅

In December 2017, we awarded 200 thousand RSUs to our employees. Such RSU awards will vest 100% after one full year of service.

⋅

In January 2018, we awarded approximately 67 thousand RSUs to each of our 4 non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. Such awards vest 25% at the end of each calendar quarter in 2018. Distributions of stock under the January 2018 award will be distributed on the first business day of the year after vesting.

2014 Restricted Stock Unit Award Plan

Our 2014 RSU Plan was approved by shareholders in May 2014 and permits the grant of up to 400 thousand shares of our common stock pursuant to awards under the 2014 RSU Plan. As of December 31, 2017, approximately 3 thousand shares are available for award under the 2014 RSU Plan.

Information about the awards under the 2014 RSU Plan during 2016 and 2017 is as follows:

⋅

In January 2016, we awarded approximately 22 thousand RSUs to each of our 4 non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. Such awards vest 25% at the end of each calendar quarter in 2016. The portion of the RSU awards which are subject to cash settlement are also subject to marked-to market accounting and the liability recorded in the Company’s balance sheet as an estimate for such cash settlement was $27 thousand at December 31, 2016. Distributions of stock under this award are generally distributed on the first business day of the year after vesting, but such distribution can be deferred until a later date at the election of the non-employee director.

⋅

In January 2017, we awarded approximately 60 thousand RSUs to each of our 4 non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. Such awards vest 25% at the end of each calendar quarter in 2017. Distributions of stock under this award will be distributed on the first business day of the year after vesting.

Information about the distribution of shares under the 2014 RSU Plan is as follows:

⋅

In January 2016, 1 thousand RSUs from the May 2014 award and 42 thousand RSUs from the January 2015 award were distributed. There are 2 thousand RSUs from the May 2014 award which remain deferred until a future distribution date. Of the 42 thousand RSUs distributed, 33 thousand RSUs were distributed in common stock and 9 thousand RSUs were settled in cash.

⋅

In January 2017, 1 thousand RSUs from the May 2014 award and 66 thousand RSUs from the January 2016 award were distributed. There are 1 thousand RSUs from the May 1 2014 award and 22 thousand RSUs from the January 2016 award which remain deferred until a future distribution date. Of the 67 thousand RSUs distributed, 49 thousand RSUs were distributed in common stock and 18 thousand RSUs were settled in cash.

⋅

In January 2018, all outstanding RSUs from the 2014 RSU Plan were distributed. There are no outstanding awards which remain deferred until a future distribution date. Of the approximately 261 thousand RSUs distributed, 238 thousand RSUs were distributed in common stock and 24 thousand RSUs were settled in cash.

INCOME TAXES

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 13 – INCOME TAXES

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017 and requiring adjustment to 2017 deferred taxes. The Company has calculated its best estimate of the impact of the Act in its year-end income tax provision in accordance with its understanding of the Act and guidance available as of the date of this filing and as a result had no adjustment to record as an additional income tax expense in the fourth quarter of 2017, the period in which the legislation was enacted.

On December 22, 2017, Staff Accounting Bulletin No. 118 ("SAB 118") was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. In accordance with SAB 118, the Company has remeasured its deferred tax assets and liabilities and adjusted its deferred tax balances to reflect the lower enacted U.S. corporate tax rate resulted in an income tax expense of $26.6 million which is included as a discrete item in the 2017 income tax provision. Overall, there was no impact to the tax provision as a result of offsetting reduction of the valuation allowance. This deferred tax expense and valuation allowance were provisional amounts and reasonable estimates at December 31, 2017.

Provision for Income Taxes

The reconciliation between our provision for income taxes and the amounts computed by multiplying our loss before taxes by the U.S. statutory tax rate is as follows (in thousands):

	December 31,
	2017		2016
Benefit at U.S. statutory 34% tax rate	$	(1,978)	$	(2,512)
State taxes (benefit), net of federal effect		(203)		(254)
State research and development tax credits		105		49
Federal research and development tax credits		(70)		-
Share-based compensation		116		159
Federal AMT tax credit		(135)		-
Other		(3)		2
Tax Cuts and Jobs Act of 2017		26,603		-
Change in valuation allowance		(24,570)		2,556
(Benefit) provision for income taxes	$	(135)	$	-

Deferred Tax Assets and Valuation Allowance

Deferred tax assets reflect the tax effects of net operating losses (“NOLs”), tax credit carryovers, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The most significant item of our deferred tax assets is derived from our Federal NOLs. We have approximately $167.7 million gross Federal NOLs at December 31, 2017 however we believe the ability for us to use these NOLs to offset any future taxable income is severely limited as prescribed under Internal Revenue Code (“IRC”) Section 382. We have estimated and recorded an amount for the likely limitation to our deferred tax asset, thereby reducing the aggregate estimated benefit of the Federal NOLs available to us of approximately $1.0 million. We believe the gross Federal NOL benefit we can utilize to offset taxable income is less than $150 thousand annually. Any unused Federal NOL benefit from the annual limitation can be accumulated and carried forward to the subsequent year and will expire if not used in accordance with the NOL carried forward term of 20 years or 2037. Future common stock transactions may cause another qualifying event under IRC 382 which may further limit our utilization of our NOLs.

The components of our deferred tax assets are as follows (in thousands):

	December 31,
	2017		2016
Deferred tax assets:
Estimated future value of NOLs
- Federal	$	1,028	$	47,192
- State		1,276		2,135
Research and development tax credits
- Federal		1,231		1,161
- State		-		159
Share-based compensation		66		57
Other, net		203		332
Total deferred taxes		3,804		51,036
Valuation allowance		(3,804)		(51,036)
Net deferred tax assets	$	-	$	-

Realization of deferred tax assets is dependent upon future earnings, if any, and the timing and amount of which may be uncertain. Valuation allowances are placed on deferred tax assets when uncertainty exists on their near term utilization. We make periodic reviews of our valuation allowances and fluctuations can occur. Those fluctuations may be reflected as income tax expenses or benefits in the period they occur. We continue to maintain full valuation allowance against all of our deferred tax assets at December 31, 2017 due to uncertainties with respect to future utilization of net operating loss carryforwards. If in the future it is determined that amounts of our deferred tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and a benefit from income taxes in such period would be recognized.

Uncertainty in Income Taxes

We adopted FASB’s statement regarding accounting for uncertainty in income taxes which defined the threshold for recognizing the benefits of tax-return positions in the consolidated financial statements as "more-likely-than-not" to be sustained by the taxing authorities. Our adoption of the standard did not result in establishing a contingent tax liability reserve or a corresponding charge to retained earnings. At each of December 31, 2017 and 2016, we had no liability for income tax associated with uncertain tax positions. If in the future we establish a contingent tax liability reserve related to uncertain tax positions, our practice will be to recognize the interest in interest expense and the penalties in other non-operating expense.

The Company files federal and state income tax returns and in the normal course of business the Company is subject to examination by these taxing authorities. As of December 31, 2017, the Company’s tax years of 2014, 2015 and 2016 are subject to examination by the taxing authorities. With few exceptions, we believe the Company is no longer subject to U.S. Federal, State and local examinations by taxing authorities for years before 2014.

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 14 – COMMITMENTS AND CONTINGENCIES

Reglan®/Metoclopramide Litigation

Halsey Drug Company, as predecessor to us, was named along with numerous other companies as a defendant in cases filed in three separate state coordinated litigations pending in Pennsylvania, New Jersey and California, respectively captioned In re: Reglan®/Metoclopramide Mass Tort Litigation, Philadelphia County Court of Common Pleas, January Term, 2010, No. 01997; In re: Reglan Litigation, Superior Court of New Jersey, Law Division, Atlantic County, Case No. 289, Master Docket No. ATL-L-3865-10; and Reglan/Metoclopramide Cases, Superior Court of California, San Francisco County, Judicial Council Coordination Proceeding No. 4631, Superior Court No.: CJC-10-004631. In addition, we were served with a similar complaint by two individual plaintiffs in Nebraska federal court, which plaintiffs voluntarily dismissed in December 2014. In this product liability litigation against numerous pharmaceutical product manufacturers and distributors, including Acura, plaintiffs claim injuries from their use of the Reglan brand of metoclopramide and generic metoclopramide.

In the lawsuits filed to date, plaintiffs have not confirmed they ingested any of the generic metoclopramide manufactured by us. We discontinued manufacture and distribution of generic metoclopramide more than 20 years ago. In addition, we believe the June 23, 2011 decision by the U.S. Supreme Court in PLIVA v. Mensing (“Mensing decision”) holding that state tort law failure to warn claims against generic drug companies are pre-empted by the 1984 Hatch-Waxman Act Amendments and federal drug regulations will assist us in favorably resolving these cases.

In New Jersey, Generic Defendants, including Acura, filed dispositive motions based on the Mensing decision, which the Court granted with a limited exception. In June 2012, the New Jersey trial court dismissed all of the New Jersey cases pending against us with prejudice.

In Pennsylvania, the trial court proceedings were stayed on January 12, 2017. On June 15, 2017, the Court entered an Order approving a stipulation which dismisses nearly all of the individual cases against us based upon lack of product identification without prejudice and provides for these cases to be dismissed finally, with prejudice, on June 15, 2018, or at an earlier date in each individual case, if all parties are dismissed. Acura is in the process of seeking voluntary dismissal without prejudice of the de minimis number of remaining Pennsylvania cases pending against Acura on the basis of lack of product identification. We expect that these remaining few cases will be dismissed based on lack of product identification and the Court will finally dismiss the Pennsylvania-based litigation against us with prejudice in 2018. Legal fees related to this matter are currently covered by our insurance carrier.

In California, on May 24, 2016, the Court entered an Order approving a stipulation which stays the individual cases against us and provides for an agreed upon dismissal protocol for all cases where is a lack of product identification. On January 13, 2017, the Court also entered a general stay of this entire litigation. To date, none of these plaintiffs have confirmed they ingested any of the generic metoclopramide manufactured by us. Therefore, we expect that the lawsuits filed against us will be dismissed voluntarily with prejudice in 2018. Legal fees related to this matter are currently covered by our insurance carrier.

As any potential loss is neither probable nor estimable, we have not accrued for any potential loss related to these matters as of December 31, 2017 and we are presently unable to determine if any potential loss would be covered by our insurance carrier.

DES Litigation

On April 12, 2018, an action was commenced against the Company and over twenty-five other pharmaceutical manufacturers in New York State Supreme Court, New York County, captioned Cotto et al. v. Abbott Laboratories, Inc., et al (index 153339/2018). The Complaint contains seven causes of action, including negligence, strict liability, and breach of warranty, wrongful death, among others, in connection with the alleged exposure of the deceased plaintiff in utero to diethylstilbestrol (DES) in the 1950s as the result of the ingestion of the drug by her mother or grandmother. The plaintiffs are the personal representative of the deceased and her two daughters. The plaintiffs were unable to determine which of the defendants produced the DES used by the deceased, but regardless seeks to hold all defendants jointly and severally liable. The Complaint seeks $10.0 million in compensatory and $10.0 million in punitive damages on each of five counts and damages in an amount to be determined for wrongful death and additional punitive damages in an unstated amount. As any potential loss is neither probable nor estimable, we have not accrued for any potential loss related to these matters as of December 31, 2017. We are presently unable to determine if any potential loss would be covered by any of our current or former insurance carriers.

Purdue Pharma Settlement

In April 2015, Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc. (collectively, “Purdue”) commenced a patent infringement lawsuit against us and our Oxaydo product licensee Egalet US, Inc. and its parent Egalet Corporation in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s U.S. Patent No. 8,389,007 (the “ 007 patent”). In April 2016, Purdue commenced a second patent infringement lawsuit against us and Egalet in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s newly issued U.S. Patent No. 9,308,171 (the “171 Patent”). The actions regarding the 007 Patent and the 171 Patent are collectively referred to as the “Actions”. On April 6, 2016, we filed a petition for Inter Partes Review (the “IPR Review”) with the U.S. Patent and Trademark Office (“USPTO”) seeking to invalidate Purdue’s 007 Patent.

On May 20, 2016, Purdue on behalf of themselves and certain affiliates, Egalet Corporation, on behalf of itself and its affiliates and we, on behalf of ourselves and our affiliates entered into a settlement agreement (the “Settlement Agreement”) to settle the Actions and the IPR Review. Under the Settlement Agreement the parties dismissed or withdrew the Actions, requested that the USPTO terminate the IPR Review and exchanged mutual releases. No payments were made under the Settlement Agreement.

The Settlement Agreement also provides that Purdue will not, in the future, assert certain Purdue U.S. patents, including the 007 Patent, the 171 Patent and related technologies (the “Purdue Patents”) against any Acura Settlement Product or Egalet Settlement Product (except generally in an action or interference by Acura or Egalet challenging a Purdue Patent). Acura Settlement Products and Egalet Settlement Products are certain immediate-release and extended-release products, including Oxaydo. In addition, the Settlement Agreement provides that Purdue will not challenge, with certain exceptions, the Acura/Egalet Patents with respect to the Purdue Settlement Products (as defined below) and that Purdue provides Acura and/or Egalet certain waivers of non-patent marketing exclusivity with respect to Purdue Settlement Products.

The Settlement Agreement also provides that Acura and Egalet will not, in the future, assert certain Acura and/or Egalet U.S. patents (the “Acura/Egalet Patents”), including Acura’s Aversion® Technology patents, against any Purdue Settlement Products (except generally in an action or interference by Purdue challenging an Acura/Egalet Patent). Purdue Settlement Products are certain immediate-release and extended-release products. In addition, the Settlement Agreement provides that Acura and Egalet will not challenge, with certain exceptions, the Purdue Patents with respect to the Acura Settlement Products and Egalet Settlement Products and that Acura and Egalet provide Purdue certain waivers of non-patent marketing exclusivity with respect to the Acura Settlement Products and Egalet Settlement Products. In addition, Purdue has certain rights to negotiate to exclusively distribute an authorized generic version of certain Egalet Settlement Products, including, in some circumstances, Oxaydo® and other products using Acura’s Aversion® Technology if licensed to Egalet.

The Settlement Agreement specifically excludes our patents related to our Impede® and Limitx™ technologies from the scope of the Acura/Egalet Patents under the Settlement Agreement.

In December 2014, the Company entered into an agreement with Purdue Pharma L.P. to settle a patent interference action regarding certain intellectual property held by Acura (U.S. Patent No. 8,101,630). The dispute centered upon the issue of which company has priority in developing the invention. The parties agreed to forgo protracted litigation and the uncertainties arising therefrom by entering an agreement whereby the Company conceded Purdue Pharma’s claim of priority in exchange for certain financial consideration to us including an immediate non-refundable payment of $500 thousand. In June 2015, the Company received an additional $250 thousand payment from Purdue Pharma relating to the December 2014 agreement.

Egalet Agreement covering Oxaydo

On January 7, 2015, we and Egalet entered into a Collaboration and License Agreement (the “Egalet Agreement”) to commercialize Aversion Oxycodone (formerly known as Oxecta®) under our tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Egalet Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Egalet and Egalet is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States. Eaglet launched Oxaydo in the United States late in the third quarter of 2015.

In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet is responsible for the fees and expenses relating to the Oxaydo NDA and product line extensions of Oxaydo, provided that Egalet will pay a substantial majority of the expenses and we will pay for the remaining fees and expenses relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States. Egalet will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion. At December 31, 2017 and 2016, we have accrued approximately $328 thousand and $150 thousand, respectively, of these potential cost sharing reimbursable expenses under the Egalet Agreement.

Facility Lease

The Company leases administrative office space in Palatine, Illinois on a month to month basis at the rate of approximately 2 thousand per month.

SUBSEQUENT EVENT

12 Months Ended

Dec. 31, 2017

Subsequent Events [Abstract]

SUBSEQUENT EVENT

NOTE 15 – SUBSEQUENT EVENT

Loan Due January 2, 2020

During the second quarter of 2018, we borrowed a total of $1.0 million from John Schutte and issue a promissory note (the Schutte Note), in that principal amount to him. The Schutte Note bears interest at prime plus 2.0%, and matures on January 2, 2020, at which time all principal and interest is due, and is unsecured until all obligations to Oxford are satisfied at which time we are required to grant a security interest to Mr. Schutte in all of our assets. Events of default under the Schutte Note are limited to bankruptcy defaults and failure to pay interest and principal when due on January 2, 2020. In addition, Mr. Schutte and Oxford entered into a subordination agreement, approved by us and our subsidiary, pursuant to which Mr. Schutte subordinated the Schutte Note to our obligations to Oxford under the Oxford Loan Agreement. The Schutte Note may be prepaid at any time in whole or in part, however while Oxford’s loan is outstanding such prepayment will require Oxford’s consent. Also, in connection with the loan, we and Oxford entered into a fourth amendment to the Oxford Loan Agreement. Pursuant to the fourth amendment, Oxford provided a waiver of compliance with the unqualified audit opinion covenant in connection with our receipt of our auditor’s opinion with a going concern explanatory paragraph for our 2017 financial statements and allowed us to deliver financial statements up to 160 days after year end, instead of up to 120 days after year end.

SUPPLEMENTARY DATA - QUARTERLY RESULTS OF OPERATION (Unaudited)

Selected unaudited quarterly consolidated financial data is shown below (in thousands except per share amounts):

	For Three Month Periods Ended
	Mar. 31, 2017		June 30, 2017		Sept. 30, 2017		Dec. 31, 2017
Net revenues	$	2,717	$	92	$	83	$	74
Operating expenses		2,135		2,083		2,145		1,828

Operating income (loss)		582		(1,991)		(2,062)		(1,754)
Net income (loss)	$	405	$	(2,149)	$	(2,200)	$	(1,738)

Basic income (loss) per share	$	0.03	$	(0.18)	$	(0.12)	$	(0.08)
Diluted income (loss) per share	$	0.03	$	(0.18)	$	(0.12)	$	(0.08)

	For Three Month Periods Ended
	Mar. 31, 2016		June 30, 2016		Sept. 30, 2016		Dec. 31, 2016
Net revenues	$	224	$	257	$	218	$	3,765
Operating expenses		3,362		3,336		2,287		2,036

Operating (loss) income		(3,138)		(3,079)		(2,069)		1,729
Net (loss) income	$	(3,384)	$	(3,288)	$	(2,250)	$	1,534

Basic (loss) income per share	$	(0.28)	$	(0.28)	$	(0.19)	$	0.13
Diluted (loss) income per share	$	(0.28)	$	(0.28)	$	(0.19)	$	0.13

(i) Year to date earnings per share may not equal sum of quarters due to rounding.

SUPPLEMENTARY DATA - QUARTERLY RESULTS OF OPERATION

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

SUPPLEMENTARY DATA - QUARTERLY RESULTS OF OPERATION

SUPPLEMENTARY DATA - QUARTERLY RESULTS OF OPERATION (Unaudited)

Selected unaudited quarterly consolidated financial data is shown below (in thousands except per share amounts):

	For Three Month Periods Ended
	Mar. 31, 2017		June 30, 2017		Sept. 30, 2017		Dec. 31, 2017
Net revenues	$	2,717	$	92	$	83	$	74
Operating expenses		2,135		2,083		2,145		1,828

Operating income (loss)		582		(1,991)		(2,062)		(1,754)
Net income (loss)	$	405	$	(2,149)	$	(2,200)	$	(1,738)

Basic income (loss) per share	$	0.03	$	(0.18)	$	(0.12)	$	(0.08)
Diluted income (loss) per share	$	0.03	$	(0.18)	$	(0.12)	$	(0.08)

	For Three Month Periods Ended
	Mar. 31, 2016		June 30, 2016		Sept. 30, 2016		Dec. 31, 2016
Net revenues	$	224	$	257	$	218	$	3,765
Operating expenses		3,362		3,336		2,287		2,036

Operating (loss) income		(3,138)		(3,079)		(2,069)		1,729
Net (loss) income	$	(3,384)	$	(3,288)	$	(2,250)	$	1,534

Basic (loss) income per share	$	(0.28)	$	(0.28)	$	(0.19)	$	0.13
Diluted (loss) income per share	$	(0.28)	$	(0.28)	$	(0.19)	$	0.13

(i) Year to date earnings per share may not equal sum of quarters due to rounding.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Basis of Accounting

Basis of Accounting

Reclassifications

Reclassifications

Certain reclassifications have been made to the prior year’s amounts to conform to the current year's presentation.

Use of Estimates

Use of Estimates

Concentration of Credit Risk

Concentration of Credit Risk

Cash and Cash Equivalents

Cash and Cash Equivalents

Fair Value Measurements

Fair Value Measurements

Share-based Compensation Expense

Share-based Compensation Expense

We have several share-based compensation plans covering stock options and RSUs for our employees and directors, which are described more fully in Note 11.

Our share-based compensation expense recognized in the Company’s results of operations from all types of noncash and cash-portioned instruments issued comprised the following (in thousands):

	Year Ended December 31,
	2017		2016
Research and development expense:
Stock option awards	$	136	$	167
RSU awards		3		-
	$	139	$	167

Selling, marketing, general and administrative expense:
Stock option awards		203		301
RSU awards		156		143
	$	359	$	444

Total share-based compensation expense	$	498	$	611

Property, Plant and Equipment

Property, Plant and Equipment

Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the related assets. The estimated useful lives of the major classification of depreciable assets are:

Building and improvements	10 - 40 years
Land and improvements	20 - 40 years
Machinery and equipment	7 - 10 years
Scientific equipment	5 - 10 years
Computer hardware and software	3 - 10 years

Intangible and Long-Lived Assets

Intangible and Long-Lived Assets

License Fee Revenue

License Fee Revenue

Collaboration Revenue

Collaboration Revenue

Royalty Revenue

Royalty Revenue

Net Product Sales

Net Product Sales

Advertising and Shipping/Handling Costs

Advertising and Shipping/Handling Costs

Debt Issuance Costs and Debt Discount

Deferred Debt Issuance Costs and Debt Discount

Research and Development Activities

Research and Development Activities

Income Taxes

Income Taxes

Basic and Diluted Net Loss Per Share of Common Stock

Basic and Diluted Net Loss Per Share

Customer Concentration

Customer Concentration

Customer	2016
Rite Aid Corporation		55	%
Cardinal Health, Inc.		13	%
McKesson Corporation		10	%

Trade accounts receivable from certain of our customers at December 31, 2016 accounting for 10% or more of our gross accounts receivable is presented below.

Customer	2016
AmerisourceBergen Corporation		35	%
McKesson Corporation		24	%
Cardinal Health, Inc.		19	%
The Kroger Co.		18	%
Rite Aid Corporation		**

Recent Accounting Pronouncements

Recent Accounting Pronouncements

New accounting standards which have been adopted on or before December 31, 2017

Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern

Statements of Cash Flows - Restricted Cash

Business Combinations – Clarifying the Definition of a Business

Simplication of Employee Share-Based Payment Accounting

Simplifying the Measurement of Inventory

New accounting standards which have not yet been adopted on or before December 31, 2017

Revenue from Contracts with Customers

Scope of Modification Accounting, Stock Based Compensation

Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments

Leases

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Non-Cash Share-Based Compensation Expense

Our share-based compensation expense recognized in the Company’s results of operations from all types of noncash and cash-portioned instruments issued comprised the following (in thousands):

	Year Ended December 31,
	2017		2016
Research and development expense:
Stock option awards	$	136	$	167
RSU awards		3		-
	$	139	$	167

Selling, marketing, general and administrative expense:
Stock option awards		203		301
RSU awards		156		143
	$	359	$	444

Total share-based compensation expense	$	498	$	611

Estimated Lives of Major Classification of Depreciable Assets

The estimated useful lives of the major classification of depreciable assets are:

Building and improvements	10 - 40 years
Land and improvements	20 - 40 years
Machinery and equipment	7 - 10 years
Scientific equipment	5 - 10 years
Computer hardware and software	3 - 10 years

Concentration of Risk, by Risk Factor

Customer	2016
Rite Aid Corporation		55	%
Cardinal Health, Inc.		13	%
McKesson Corporation		10	%

Trade accounts receivable from certain of our customers at December 31, 2016 accounting for 10% or more of our gross accounts receivable is presented below.

Customer	2016
AmerisourceBergen Corporation		35	%
McKesson Corporation		24	%
Cardinal Health, Inc.		19	%
The Kroger Co.		18	%
Rite Aid Corporation		**

INVENTORIES (Tables)

12 Months Ended

Dec. 31, 2017

Inventory Disclosure [Abstract]

Inventories

Inventories at December 31, 2016 are summarized as follows (in thousands):

	December 31,
	2016
Raw and packaging materials	$	98
Finished goods		243
Total		341
Less: reserve for finished goods		(32)
Net inventories	$	309

Inventory Reserve

Inventory reserve activity during the years ended December 31, 2017 and 2016 was as follows (in thousands):

	2017		2016
Beginning of year	$	32	$	70
Reserve expense - finished goods		-		26
		32		96
Inventory write-offs - finished goods		(32)		(64)
End of year	$	-	$	32

DEBT (Tables)

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Schedule of Debt

Our debt activity at December 31, 2017 is summarized below (in thousands):

Current Debt	Current		Long-term		Total
Balance at Jan. 1, 2017	$	2,521	$	2,979	$	5,500
Principal payments		(2,760)		-		(2,760)
Classification		2,979		(2,979)		-
Balance at Dec. 31, 2017	$	2,740	$	-	$	2,740

Debt Discount	Current		Long-term		Total
Balance at Jan. 1, 2017	$	(98)	$	-	$	(98)
Amortization expense		66		-		66
Classification		-		-		-
Balance at Dec. 31, 2017	$	(32)	$	-	$	(32)

Deferred Debt Issuance Costs	Current		Long-term		Total
Balance at Jan. 1, 2017	$	(47)	$	-	$	(47)
Amortization expense		33		-		33
Classification		-		-		-
Balance at Dec. 31, 2017	$	(14)	$	-	$	(14)

Current Debt, net at Dec. 31, 2017	$	2,694	$	-	$	2,694

Schedule of Interest Expense

Our interest expense consisted of the following (in thousands):

	Year Ended December 31,
	2017		2016
Interest expense:
Term loan	$	497	$	748
Debt discount		66		95
Debt issue costs		33		50
Total interest expense	$	596	$	893

COMMON STOCK WARRANTS (Tables)

12 Months Ended

Dec. 31, 2017

Stockholders Equity Note [Abstract]

Schedule Of Common Stock Warrant Activity

Our warrant activity during the years ended December 31, 2017 and 2016 is shown below (in thousands except price data):

	December 31,
	2017				2016
	Number		WAvg Exercise Price		Number		WAvg Exercise Price
Outstanding, Jan. 1		60	$	2.52		60	$	2.52
Issued		1,782		0.53		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Modification		-		-		-		-
Outstanding, Dec. 31		1,842	$	0.59		60	$	2.52

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

SHARE-BASED COMPENSATION EXPENSE (Tables)

12 Months Ended

Dec. 31, 2017

Summary Of Information About Non Vested Stock Options Disclosure Abstract [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity

A summary of our stock option plans as of December 31, 2017 and 2016 and for the year then ended consisted of the following (in thousands except exercise price):

	Year Ended December 31,
	2017				2016
	Number of Options		Weighted Average Exercise Price		Number of Options		Weighted Average Exercise Price
Outstanding, Jan. 1		1,397	$	15.67		1,198	$	15.67
Granted		185		0.45		199		0.92
Exercised		(1)		0.92		-		-
Forfeited or expired		(87)		7.02		-		-
Outstanding, Dec. 31		1,494	$	12.33		1,397	$	15.67
Exercisable, Dec. 31		1,224	$	14.92		1,062	$	17.41

Schedule of Nonvested Share Activity

The following table summarizes information about unvested stock options outstanding at December 31, 2017 (in thousands except price data):

	Number of Options Not Exercisable		Weighted Average Fair Value

Outstanding at Jan. 1, 2017		335	$	1.18
Granted		185		0.45
Vested		(236)		1.34
Forfeited		(14)		1.05
Outstanding at Dec. 31, 2017		270	$	0.46

Schedule of fair value of the warrants

The assumptions used in the Black-Scholes model to determine fair value for the 2017 and 2016 stock option grants were:

	2017			2016
Expected dividend yield		0.0	%		0.0	%
Risk-free interest rates		1.8	%		2.3	%
Average expected volatility		88	%		85	%
Expected term (years)		5			10
Weighted average grant date fair value	$	0.31		$	0.77

Schedule of Share-based Compensation, Restricted Stock Units Award Activity

A summary of the grants under the RSU Plans as of December 31, 2017 and 2016, and for the year then ended consisted of the following (in thousands):

	Year Ended December 31,
	2017				2016
	Number of RSUs		Number of Vested RSUs		Number of RSUs		Number of Vested RSUs
Outstanding, Jan. 1		91		91		45		45
Granted		438		-		88		-
Distributed		(67)		(67)		(42)		(42)
Vested		-		238		-		88
Forfeited or expired		-		-		-		-
Outstanding, Dec. 31		462		262		91		91

NET LOSS PER SHARE OF COMMON STOCK (Tables)

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Schedule Of net loss per share of common stock of basic and diluted

A reconciliation of the numerators and denominators of basic and diluted net loss per share consisted of the following (in thousands, except per share data):

	Year Ended December 31,
	2017		2016
Net loss per share - basic
Numerator: net loss	$	(5,682)	$	(7,388)
Denominator (weighted):
Common shares		15,790		11,834
Vested RSUs		113		36
Basic weighted average shares outstanding		15,903		11,870
EPS - basic	$	(0.36)	$	(0.62)

Net loss per share – assuming dilution
Numerator: net loss	$	(5,682)	$	(7,388)
Denominator (weighted):
Common shares		15,790		11,834
Vested RSUs		113		36
Stock options		-		-
Common stock warrants		-		-
Diluted weighted average shares outstanding		15,903		11,870
Net loss per share - diluted	$	(0.36)	$	(0.62)

Excluded dilutive securities:
Common stock issuable (non-weighted):
Unvested RSUs		200		-
Stock options		1,494		1,397
Common stock warrants		1,842		60
Total excluded potentially dilutive shares		3,536		1,457

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Provision for Income Taxes

The reconciliation between our provision for income taxes and the amounts computed by multiplying our loss before taxes by the U.S. statutory tax rate is as follows (in thousands):

	December 31,
	2017		2016
Benefit at U.S. statutory 34% tax rate	$	(1,978)	$	(2,512)
State taxes (benefit), net of federal effect		(203)		(254)
State research and development tax credits		105		49
Federal research and development tax credits		(70)		-
Share-based compensation		116		159
Federal AMT tax credit		(135)		-
Other		(3)		2
Tax Cuts and Jobs Act of 2017		26,603		-
Change in valuation allowance		(24,570)		2,556
(Benefit) provision for income taxes	$	(135)	$	-

Components Of Deferred Tax Assets

The components of our deferred tax assets are as follows (in thousands):

	December 31,
	2017		2016
Deferred tax assets:
Estimated future value of NOLs
- Federal	$	1,028	$	47,192
- State		1,276		2,135
Research and development tax credits
- Federal		1,231		1,161
- State		-		159
Share-based compensation		66		57
Other, net		203		332
Total deferred taxes		3,804		51,036
Valuation allowance		(3,804)		(51,036)
Net deferred tax assets	$	-	$	-

SUPPLEMENTARY DATA - QUARTERLY RESULTS OF OPERATION (Tables)

12 Months Ended

Dec. 31, 2017

Selected Quarterly Financial Information [Abstract]

SUPPLEMENTARY DATA - QUARTERLY RESULTS OF OPERATION

Selected unaudited quarterly consolidated financial data is shown below (in thousands except per share amounts):

	For Three Month Periods Ended
	Mar. 31, 2017		June 30, 2017		Sept. 30, 2017		Dec. 31, 2017
Net revenues	$	2,717	$	92	$	83	$	74
Operating expenses		2,135		2,083		2,145		1,828

Operating income (loss)		582		(1,991)		(2,062)		(1,754)
Net income (loss)	$	405	$	(2,149)	$	(2,200)	$	(1,738)

Basic income (loss) per share	$	0.03	$	(0.18)	$	(0.12)	$	(0.08)
Diluted income (loss) per share	$	0.03	$	(0.18)	$	(0.12)	$	(0.08)

	For Three Month Periods Ended
	Mar. 31, 2016		June 30, 2016		Sept. 30, 2016		Dec. 31, 2016
Net revenues	$	224	$	257	$	218	$	3,765
Operating expenses		3,362		3,336		2,287		2,036

Operating (loss) income		(3,138)		(3,079)		(2,069)		1,729
Net (loss) income	$	(3,384)	$	(3,288)	$	(2,250)	$	1,534

Basic (loss) income per share	$	(0.28)	$	(0.28)	$	(0.19)	$	0.13
Diluted (loss) income per share	$	(0.28)	$	(0.28)	$	(0.19)	$	0.13

OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended									12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	May 14, 2018	Dec. 27, 2013
Cash, Cash Equivalent And Marketable Securities		$ 2,200								$ 2,200
Working Capital Deficit		2,100								2,100
Retained Earnings (Accumulated Deficit), Total		(380,380)				$ (374,698)				(380,380)	$ (374,698)
Operating Income (Loss), Total		(1,754)	$ (2,062)	$ (1,991)	$ 582	1,729	$ (2,069)	$ (3,079)	$ (3,138)	(5,225)	(6,557)
Net Income (Loss) Attributable to Parent, Total		(1,738)	$ (2,200)	$ (2,149)	$ 405	$ 1,534	$ (2,250)	$ (3,288)	$ (3,384)	(5,682)	$ (7,388)
Debt Instrument, Face Amount													$ 10,000
Loan Agreement With Oxford [Member]
Long-term Line of Credit		$ 2,700								$ 2,700
Subsequent Event [Member] \| Schutte Note [Member]
Debt Instrument, Face Amount	$ 1,000
Proceeds from Issuance of Long-term Debt	$ 1,000
Subsequent Event [Member] \| Loan Agreement With Oxford [Member]
Long-term Line of Credit												$ 1,800

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Non-Cash Share-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 498	$ 611
Research and Development Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	139	167
Research and Development Expense \| Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	136	167
Research and Development Expense \| Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	3	0
Selling, General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	359	444
Selling, General and Administrative \| Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	203	301
Selling, General and Administrative \| Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 156	$ 143

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of the Major Classification of Depreciable Assets (Detail)	12 Months Ended
	Dec. 31, 2017
Building and Building Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Building and Building Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Land Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Land Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	20 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Scientific Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Scientific Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Computer Hardware and Software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Computer Hardware and Software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Risk by Risk Factor (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%
Rite Aid Corporation \| Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage		55.00%
Rite Aid Corporation \| Accounts Receivable
Concentration Risk [Line Items]
Concentration Risk, Percentage
Cardinal Health, Inc. \| Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage		13.00%
Cardinal Health, Inc. \| Accounts Receivable
Concentration Risk [Line Items]
Concentration Risk, Percentage		19.00%
AmerisourceBergen Corporation \| Accounts Receivable
Concentration Risk [Line Items]
Concentration Risk, Percentage		35.00%
McKesson Corporation \| Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage		10.00%
McKesson Corporation \| Accounts Receivable
Concentration Risk [Line Items]
Concentration Risk, Percentage		24.00%
Kroger Foods \| Accounts Receivable
Concentration Risk [Line Items]
Concentration Risk, Percentage		18.00%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended	12 Months Ended
	Mar. 31, 2017	Mar. 16, 2017	Oct. 31, 2016	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Financing Receivable, Impaired [Line Items]
Royalty Revenue, Total					$ 300	$ 149
Other Revenue, Net					59	392
Asset Impairment Charges				$ 82	0	$ 82
Kempharm Agreement [Member]
Financing Receivable, Impaired [Line Items]
Proceeds From Upfront Payment			$ 3,500
Main Pointe Agreement [Member]
Financing Receivable, Impaired [Line Items]
Royalty Revenue, Total					$ 19
Proceeds from License Fees Received	$ 2,500
Licensing Agreement, Royalty Percentage		7.50%
Royalty Revenue, Payment Method, Description		Such royalty shall be payable for sales made during each calendar quarter and payment will be remitted within forty-five (45) days after the end of the quarter to which it relates
Sales Revenue, Net [Member]
Financing Receivable, Impaired [Line Items]
Concentration Risk, Percentage					10.00%
Sales Revenue, Net [Member] \| Minimum [Member]
Financing Receivable, Impaired [Line Items]
Concentration Risk, Percentage					10.00%

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended				12 Months Ended
	Oct. 09, 2015	Mar. 31, 2017	Mar. 16, 2017	Oct. 31, 2016	Apr. 30, 2014	Dec. 31, 2017	Dec. 31, 2016
License Development and Commercialization Agreement [Line Items]
Agreement Termination Notice Description						Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalets launch of Oxaydo. Termination does not affect a partys rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalets supply of Oxaydo for a transition period.
Amortization of Intangible Assets						$ 207	$ 207
License Agreement Option Products Description		In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). Such Option Products include the product candidate Loratadine with pseudoephedrine. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.
Patents [Member]
License Development and Commercialization Agreement [Line Items]
Payment for Termination					$ 2,000
Egalet Agreement
License Development and Commercialization Agreement [Line Items]
Payment for Termination					$ 2,000
Licenses Revenue	$ 5,000
Proceeds from Milestone Payment On Agreement	$ 2,500
Amortization of Intangible Assets						208	$ 208
Finite-Lived Intangible Asset, Useful Life					9 years 8 months 12 days
Finite-Lived Intangible Assets, Amortization Expense, Year Two						$ 208
Main Pointe Agreement [Member]
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		$ 2,500	$ 2,500
Asset Transferred, License Agreement		$ 309	$ 309
Licensing Agreement, Royalty Percentage		7.50%	7.50%
Main Pointe Agreement [Member] \| UNITED KINGDOM
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		$ 1,000
Main Pointe Agreement [Member] \| JAPAN
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		500
Main Pointe Agreement [Member] \| South Korea [Member]
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		$ 250
Kempharm Agreement [Member]
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received				$ 3,500
Kempharm Agreement [Member] \| Minimum
License Development and Commercialization Agreement [Line Items]
Additional Upfront Payment Receivable				$ 1,000

INVENTORIES - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Inventory [Line Items]
Raw and packaging materials		$ 98
Finished goods		243
Total		341
Less: reserve for finished goods	$ 0	(32)	$ (70)
Net inventories	$ 0	$ 309

INVENTORIES - Inventory Reserve (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Inventory [Line Items]
Beginning of year	$ 32	$ 70
Reserve expense - finished goods	0	26
Inventory Reserve Expense	32	96
Inventory write-offs - finished goods	(32)	(64)
End of year	$ 0	$ 32

PROPERTY, PLANT AND EQUIPMENT (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 2,512	$ 2,807
Less: impairment reserve	0	(82)
Less: accumulated depreciation	(1,833)	(1,858)
Total property, plant and equipment, net	679	867
Building and improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,273	1,273
Scientific equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	598	598
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	107	109
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	275	568
Land and improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	162	162
Other personal property
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	70	70
Office equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 27	$ 27

PROPERTY, PLANT AND EQUIPMENT - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Depreciation	$ 100	$ 100
Impairment Of Property, Plant and Equipment, Reserve	$ 0	$ (82)

ACCRUED EXPENSES (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounts Payable and Accrued Liabilities [Line Items]
Cost sharing expenses under license agreements	$ 328	$ 150
Other fees and services	36	47
Payroll, payroll taxes and benefits	70	116
Professional services	149	232
Clinical, non-clinical and regulatory services	326	131
Marketing, advertising, and promotion	0	10
Property taxes	16	16
Franchise taxes	14	1
Total	$ 939	$ 703

DEBT - Summary of Debt (Detail) $ in Thousands	12 Months Ended
DEBT - Summary of Debt (Detail) $ in Thousands	Dec. 31, 2017 USD ($)
Current Debt
Balance at Jan. 1, 2017	$ 5,500
Principal payments	(2,760)
Classification	0
Balance at Dec. 31, 2017	2,740
Debt Discount
Balance at Jan. 1, 2017	(98)
Amortization expense	66
Classification	0
Balance at Dec. 31, 2017	(32)
Deferred Debt Issuance Costs
Balance at Jan. 1, 2017	(47)
Amortization expense	33
Classification	0
Balance at Dec. 31, 2017	(14)
Current Debt, net at Dec. 31, 2017	2,694
Long-term [Member]
Current Debt
Balance at Jan. 1, 2017	2,979
Principal payments	0
Classification	(2,979)
Balance at Dec. 31, 2017	0
Debt Discount
Balance at Jan. 1, 2017	0
Amortization expense	0
Classification	0
Balance at Dec. 31, 2017	0
Deferred Debt Issuance Costs
Balance at Jan. 1, 2017	0
Amortization expense	0
Classification	0
Balance at Dec. 31, 2017	0
Current Debt, net at Dec. 31, 2017	0
Current [Member]
Current Debt
Balance at Jan. 1, 2017	2,521
Principal payments	(2,760)
Classification	2,979
Balance at Dec. 31, 2017	2,740
Debt Discount
Balance at Jan. 1, 2017	(98)
Amortization expense	66
Classification	0
Balance at Dec. 31, 2017	(32)
Deferred Debt Issuance Costs
Balance at Jan. 1, 2017	(47)
Amortization expense	33
Classification	0
Balance at Dec. 31, 2017	(14)
Current Debt, net at Dec. 31, 2017	$ 2,694

DEBT - Interest Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
DEBT - Interest Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Interest expense:
Term loan	$ 497	$ 748
Debt discount	66	95
Debt issue costs	33	50
Total interest expense	$ 596	$ 893

DEBT - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands			1 Months Ended		12 Months Ended
	May 14, 2018	Jan. 07, 2015	Jul. 31, 2017	Oct. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2018	Dec. 31, 2013	Dec. 27, 2013
Debt Instrument [Line Items]
Debt instrument principal amount									$ 10,000
Debt default long term debt percentage									13.35%
Debt Instrument, Maturity Date					Dec. 01, 2018
Debt instrument, fee amount					$ 50
Debt consulting placement fee					100
Debt related commitment fees and debt issuance costs					33	$ 50
Debt instrument unamortized discount					32	98
Debt instrument Cash Maintenance		$ 2,500
Repayments of Debt					2,760	2,540
Debt Instrument, Periodic Payment					$ 260
Debt Instrument, Interest Rate, Effective Percentage					10.16%
Proceeds from Issuance or Sale of Equity				$ 6,000
Interest Payable, Current					$ 700	0
Proceeds from Issuance of Private Placement			$ 4,000
Restricted Cash and Cash Equivalents, Current					0	2,500
Main Pointe Agreement [Member]
Debt Instrument [Line Items]
Upfront Payments Received			2,500
Oxford Term Loan Agreement [Member]
Debt Instrument [Line Items]
Restricted Cash and Cash Equivalents, Current			$ 2,500
Term Loan [Member]
Debt Instrument [Line Items]
Debt related commitment fees and debt issuance costs					231
Proceeds from Issuance or Sale of Equity				2,500
Interest Payable, Current					700	$ 559
Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage									8.35%
Repayments of Debt		$ 5,000		5,000
Proceeds from Issuance or Sale of Equity				2,500
Maximum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 7.98
Minimum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.52
Proceeds from Issuance or Sale of Equity				$ 3,000
Subsequent Event [Member] \| Schutte Note [Member]
Debt Instrument [Line Items]
Debt instrument principal amount							$ 1,000
Debt Instrument, Maturity Date	Jan. 02, 2020
Warrant
Debt Instrument [Line Items]
Debt instrument unamortized discount					$ 400
Warrants to purchase common stock					60
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 7.98			$ 2.52
Warrants, expiry date					December 27, 2020
Additions To Debt Instrument Unamortized Discount		$ 33
First Revenue Event Occurs
Debt Instrument [Line Items]
Debt instrument periodic payment terms balloon payment to be paid					$ 795
Prior To December 27 2015
Debt Instrument [Line Items]
Debt instrument prepayment percentage					1.00%

RELATED PARTY TRANSACTIONS- Additional Information(Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended
	Jul. 31, 2017	Mar. 31, 2017	Mar. 16, 2017	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Number Of Common Stock Need To Hold To Designate As Director	600,000
Royalty Receivable					$ 71	$ 50
Schutte Note [Member] \| Subsequent Event [Member]
Proceeds from Issuance of Long-term Debt				$ 1,000
Investor [Member]
Sale of Stock, Number of Shares Issued in Transaction	8,912,655
Sale of Stock, Price Per Share	$ 0.4488
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	(0.2)
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.528
Private Placement [Member] \| Investor [Member]
Sale of Stock, Consideration Received on Transaction	$ 4,000
Sale Of Stock, Issue Price Description	85
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.528
Warrants Not Settleable in Cash, Fair Value Disclosure					495
Class Of Warrants Or Rights, Expiry Period	5 years
Main Pointe Agreement [Member]
Proceeds from License Fees Received		$ 2,500	$ 2,500
Asset Transferred, License Agreement		$ 309	$ 309
Licensing Agreement, Royalty Percentage		7.50%	7.50%
Royalty Receivable					$ 13

COMMON STOCK WARRANTS - Schedule Of Common Stock Warrant Activity (Detail) - Warrant [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Number of Options
Number of Options Outstanding, beginning	60	60
Number of Options, Issued	1,782	0
Number of Options, Exercised	0	0
Number of Options, Expired	0	0
Number of Options, Modification	0	0
Number of Options Outstanding, ending	1,842	60
Weighted Average Exercise Price
Weighted Average Exercise Price, beginning	$ 2.52	$ 2.52
Weighted Average Exercise Price,Issued	0.53	0
Weighted Average Exercise Price, Exercised	0	0
Weighted Average Exercise Price, Expired	0	0
Weighted Average Exercise Price, Modification	0	0
Weighted Average Exercise Price, ending	$ 0.59	$ 2.52

COMMON STOCK WARRANTS - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2017	Dec. 31, 2017	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Secured Debt			$ 10,000
Stock Issued During Period, Value, New Issues		$ 4,000
Investor [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.528
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,782,531
Class Of Warrant Or Right Term	5 years
Investor [Member] \| Private Placement [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.528
Warrant
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares		60,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 7.98	$ 2.52
Warrant \| Private Placement [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Value, New Issues	$ 495

SHARE-BASED COMPENSATION EXPENSE - Stock Option Award Activity (Detail) - Stock Option Plan [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, beginning	1,397	1,198
Number of Options, Granted	185	199
Number of Options, Exercised	(1)	0
Number of Options, Forfeited or expired	(87)	0
Number of Options Outstanding, ending	1,494	1,397
Number of Options exercisable	1,224	1,062
Weighted Average Exercise Price, beginning	$ 15.67	$ 15.67
Weighted Average Exercise Price, Granted	0.45	0.92
Weighted Average Exercise Price, Exercised	0.92	0
Weighted Average Exercise Price, Forfeited or expired	7.02	0
Weighted Average Exercise Price, ending	12.33	15.67
Weighted Average Exercise Price, Options exercisable	$ 14.92	$ 17.41

SHARE-BASED COMPENSATION EXPENSE - Summary of Information about Non Vested Stock Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2017 $ / shares shares
Summary Of Information About Non Vested Stock Options Disclosure [Line Items]
Outstanding, beginning \| shares	335
Granted \| shares	185
Vested \| shares	(236)
Forfeited \| shares	(14)
Outstanding, ending \| shares	270
Outstanding beginning, Weighted Average Fair Value \| $ / shares	$ 1.18
Granted, Weighted Average Fair Value \| $ / shares	0.45
Vested, Weighted Average Fair Value \| $ / shares	1.34
Forfeited, Weighted Average Fair Value \| $ / shares	1.05
Outstanding ending, Weighted Average Fair Value \| $ / shares	$ 0.46

SHARE-BASED COMPENSATION EXPENSE - Assumptions Used in Black-Scholes Model to Determine Fair Value for Stock Option Awards Granted (Detail) - Stock Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%
Risk-free interest rates	1.80%	2.30%
Average expected volatility	88.00%	85.00%
Expected term (years)	5 years	10 years
Weighted average grant date fair value	$ 0.31	$ 0.77

SHARE-BASED COMPENSATION EXPENSE - Summary of RSU Plan (Detail) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	335
Granted	185
Vested	236
Forfeited or expired	(14)
Outstanding, ending	270	335
Restricted Stock Units [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	91	45
Granted	438	88
Distributed	(67)	(42)
Vested	0	0
Forfeited or expired	0	0
Outstanding, ending	462	91
Vested Restricted Stock Units (RSUs) [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	91	45
Granted	0	0
Distributed	(67)	(42)
Vested	238	88
Forfeited or expired	0	0
Outstanding, ending	262	91

SHARE-BASED COMPENSATION EXPENSE - Additional Information (Detail) - USD ($) shares in Thousands	1 Months Ended				12 Months Ended
	Jan. 31, 2018	Dec. 31, 2017	Jan. 31, 2017	Jan. 31, 2016	Dec. 31, 2017	Nov. 30, 2017	Dec. 31, 2016	May 31, 2014
Employee Benefit Plans Disclosure [Line Items]
Unrecognized compensation cost on unvested option awards outstanding		$ 100,000			$ 100,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period					185
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value		0			$ 0
Employee Stock Option [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					1
2005 Restricted Stock Unit Award Plan [Member] \| Director [Member]
Employee Benefit Plans Disclosure [Line Items]
Deferred Compensation Arrangement with Individual, Recorded Liability		$ 41,000			$ 41,000		$ 27,000
Share Based Compensation, Non Employee Services Transaction,Cash Settlement, Percentage					40.00%
2014 Restricted Stock Unit Award Plan [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant								400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			1	1
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution			66	42
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award					3
2014 Restricted Stock Unit Award Plan [Member] \| Settled In Cash [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			22	9	18
2014 Restricted Stock Unit Award Plan [Member] \| Distributed In Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			67	42
2014 Restricted Stock Unit Award Plan [Member] \| Convertible Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			49	33
2014 Restricted Stock Unit Award Plan [Member] \| Four Non Employee Directors [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			60	22
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			25.00%	25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Description			stock, for up to 40%	stock, for up to 40%
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution				2
Deferred Compensation Arrangement with Individual, Recorded Liability							$ 27,000
2014 Restricted Stock Unit Award Plan [Member] \| Subsequent Event [Member] \| Settled In Cash [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	24
2014 Restricted Stock Unit Award Plan [Member] \| Subsequent Event [Member] \| Distributed In Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	261
2014 Restricted Stock Unit Award Plan [Member] \| Subsequent Event [Member] \| Convertible Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	238
2017 Restricted Stock Unit Award Plan [Mfember]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		1,300			1,300
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						1,500
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period		200
2017 Restricted Stock Unit Award Plan [Mfember] \| Subsequent Event [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period	67

NET LOSS PER SHARE OF COMMON STOCK (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Net loss per share - basic
Numerator: net loss	$ (1,738)	$ (2,200)	$ (2,149)	$ 405	$ 1,534	$ (2,250)	$ (3,288)	$ (3,384)	$ (5,682)	$ (7,388)
Denominator (weighted):
Common shares									15,790	11,834
Vested RSUs									113	36
Basic weighted average shares outstanding									15,903	11,870
EPS - basic	$ (0.08)	$ (0.12)	$ (0.18)	$ 0.03	$ 0.13	$ (0.19)	$ (0.28)	$ (0.28)	$ (0.36)	$ (0.62)
Net loss per share - assuming dilution
Numerator: net loss	$ (1,738)	$ (2,200)	$ (2,149)	$ 405	$ 1,534	$ (2,250)	$ (3,288)	$ (3,384)	$ (5,682)	$ (7,388)
Denominator (weighted):
Common shares									15,790	11,834
Vested RSUs									113	36
Stock options									0	0
Common stock warrants									0	0
Diluted weighted average shares outstanding									15,903	11,870
Net loss per share - diluted	$ (0.08)	$ (0.12)	$ (0.18)	$ 0.03	$ 0.13	$ (0.19)	$ (0.28)	$ (0.28)	$ (0.36)	$ (0.62)
Excluded dilutive securities, Common stock issuable (non-weighted):
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount									3,536	1,457
Restricted Stock Units (RSUs) [Member]
Excluded dilutive securities, Common stock issuable (non-weighted):
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount									200	0
Employee Stock Option [Member]
Excluded dilutive securities, Common stock issuable (non-weighted):
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount									1,494	1,397
Warrant [Member]
Excluded dilutive securities, Common stock issuable (non-weighted):
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount									1,842	60

INCOME TAXES - Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Provision For Income Taxes [Line Items]
Benefit at U.S. statutory 34% tax rate	$ (1,978)	$ (2,512)
State taxes (benefit), net of federal effect	(203)	(254)
State research and development tax credits	105	49
Federal research and development tax credits	(70)	0
Share-based compensation	116	159
Federal AMT tax credit	(135)	0
Other	(3)	2
Tax Cuts and Jobs Act of 2017	26,603	0
Change in valuation allowance	(24,570)	2,556
(Benefit) provision for income taxes	$ (135)	$ 0

INCOME TAXES - Components of Our Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Estimated future value of NOLs
- Federal	$ 1,028	$ 47,192
- State	1,276	2,135
Research and development tax credits
- Federal	1,231	1,161
- State	0	159
Share-based compensation	66	57
Other, net	203	332
Total deferred taxes	3,804	51,036
Valuation allowance	(3,804)	(51,036)
Net deferred tax assets	$ 0	$ 0

INCOME TAXES - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Line Items]
Federal NOLs		$ 167,700
U.S. statutory tax rate		35.00%
State income tax benefits		$ 1,000
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount		$ 26,603	$ 0
Operating Loss Carryforwards, Expiration Term		20 years
Operating Loss Carry Forwards Expiration Year		2037
Tax Credit Carryforward, Amount		$ 150
Scenario, Plan [Member]
Income Tax Disclosure [Line Items]
U.S. statutory tax rate	21.00%

COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
	Apr. 12, 2018	Jun. 30, 2015	Dec. 31, 2017	Dec. 31, 2014	Dec. 31, 2016
Commitments and Contingencies Disclosure [Line Items]
Accrued Cost Sharing Expenses Clinical Studies			$ 328		$ 150
Purdue Pharma [Member]
Commitments and Contingencies Disclosure [Line Items]
Litigation Settlement, Expense		$ 250		$ 500
Palatine Illinois
Commitments and Contingencies Disclosure [Line Items]
Leases administrative office space			$ 2
Scenario, Forecast [Member]
Commitments and Contingencies Disclosure [Line Items]
Gain Contingency, Unrecorded Amount	$ 10,000
Loss Contingency, Damages Sought, Value	$ 10,000

SUBSEQUENT EVENT - Additional Information (Detail) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
	May 14, 2018	Jun. 30, 2018	Dec. 31, 2017
Subsequent Event [Line Items]
Debt Instrument, Maturity Date			Dec. 01, 2018
Subsequent Event [Member] \| Schutte Note [Member]
Subsequent Event [Line Items]
Proceeds from Issuance of Long-term Debt		$ 1.0
Debt Instrument, Basis Spread on Variable Rate		2.00%
Debt Instrument, Maturity Date	Jan. 02, 2020

SUPPLEMENTARY DATA - QUARTERLY RESULTS OF OPERATION (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Schedule Of Quarterly Financial Information [Line Items]
Net revenues	$ 74	$ 83	$ 92	$ 2,717	$ 3,765	$ 218	$ 257	$ 224	$ 2,966	$ 4,464
Operating expenses	1,828	2,145	2,083	2,135	2,036	2,287	3,336	3,362	8,191	11,021
Operating (loss) income	(1,754)	(2,062)	(1,991)	582	1,729	(2,069)	(3,079)	(3,138)	(5,225)	(6,557)
Net (loss) income	$ (1,738)	$ (2,200)	$ (2,149)	$ 405	$ 1,534	$ (2,250)	$ (3,288)	$ (3,384)	$ (5,682)	$ (7,388)
Basic (loss) income per share	$ (0.08)	$ (0.12)	$ (0.18)	$ 0.03	$ 0.13	$ (0.19)	$ (0.28)	$ (0.28)	$ (0.36)	$ (0.62)
Diluted (loss) income per share	$ (0.08)	$ (0.12)	$ (0.18)	$ 0.03	$ 0.13	$ (0.19)	$ (0.28)	$ (0.28)	$ (0.36)	$ (0.62)

EMPLOYEE BENEFIT PLAN - Additional Information (Detail)	12 Months Ended
EMPLOYEE BENEFIT PLAN - Additional Information (Detail)	Dec. 31, 2017
Four Zero One K and Profit Sharing Plan [Member]
Maximum Basic Contribution Percentage Per Employee On Annual Earnings	80.00%